Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (-) -carvone, geraniol and a further essential oil component

ABSTRACT

The present invention concerns an antiviral composition comprising the following components: R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (−) carvone) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (+) carvone) and (2E)-3,7-dimethylocta-2,6-dien-1-ol (also called trans-geraniol) in combination with at least one more component chosen among essential oils components for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.

This application is a continuation and claims the benefit of pending U.S. application with the Ser. No. 13/582,784, which was filed 5 Sep. 2012.

FIELD OF THE INVENTION

The present invention relates to the pharmaceutical field. The man skilled in the art can be a virologist.

The present invention relates to compositions and methods of use thereof in treatment and prevention of diseases caused by DNA enveloped, DNA non-enveloped, RNA enveloped, RNA non-enveloped viruses.

BACKGROUND OF INVENTION

U.S. Pat. No. 4,402,950 is considered as the closest prior art as it discloses (in vitro) the antiviral activity of carvone against adenovirus type 6, which is a double stranded DNA non enveloped virus.

U.S. Pat. No. 4,402,950 discloses in its claim 1 “a process for deactivating viruses inside living human and animal organisms infected with said viruses comprising administering to one of said organisms a terpene selected from the group consisting of black pepper oil, cinnamon flower oil, cardamon oil, linallyl acetate, cinnamic aldehyde, carvone, and cis/trans citral, in a dosage amount effective to deactivate said viruses but ineffective to cause toxic effects on living cells of the living organism.”

The first column of U.S. Pat. No. 4,402,950 mentions at line that the carvone used is from the fruit of Carum carvi. The man skilled in the art will therefore easily deduct that the carvon used in U.S. Pat. No. 4,402,950 is the enantiomer “(+)-carvon”. In fact it is well known in the literature that S-(+)-Carvone is the principal constituent of the oil from caraway seeds (Carum carvi).

The difference between the present invention and the closest prior art is:

a composition comprising R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (−)-carvon) and (2E)-3,7-dimethylocta-2,6-dien-1-ol (also called trans-geraniol) in combination with at least one more component chosen among essential oils in a pharmaceutically effective concentration (see list D which is disclosed in the present invention) for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses, said diseases are those mentioned in claim 1.

The technical effect of the above mentioned difference is that an unexpected and surprising regression of lesions on the surface of the cervix occurred in vivo (between 20%-100%: see the comparative tests), while there is no medical effect occurring when any individual component is tested alone in vivo.

The objective technical problem to be solved is considered as the provision of a synergetic (alternative) antiviral composition comprising (+) carvone having an antiviral effect.

The question to be answered now is whether there is any teaching in the prior art as a whole (like U.S. Pat. No. 3,429,971) that would have prompted the skilled person, faced with the objective technical problem, to modify the closest prior art while taking account of that teaching, thereby arriving at something falling within the terms of the claims, and thus achieving what the invention achieves. The answer to this question is clearly NO. We explain why as follows:

U.S. Pat. No. 3,429,971 discloses a method of treating avian lymphomatosis induced by ES strain of lymphomatosis virus which comprises administering to a bird an effective amount of Cis-Geraniol. It is well known from a man skilled in the art that the isomers Cis-Geraniol and Trans-Geraniol have different biological/biochemical properties. This is even proved in U.S. Pat. No. 3,429,971:

The skilled person would never have combined U.S. Pat. No. 4,402,950 with U.S. Pat. No. 3,429,971 because U.S. Pat. No. 3,429,971 discloses in column 3, table 2 second and third rows:

“Trans-2,6-dimethyl-2,6,octadiene-8-ol→ No. cures: 0”.

Trans-2,6-dimethyl-2,6,octadiene-8-ol corresponds to the component “Trans-geraniol, i.e. to (2E)-3,7-dimethylocta-2,6-dien-1-ol”.

The virus mentioned in U.S. Pat. No. 3,429,971 is the avian lymphomatosis virus, which is a double stranded DNA enveloped virus (herpesviridae family).

The man skilled in the art, starting from U.S. Pat. No. 4,402,950 would be led to search a second component deactivating a virus of the same family as U.S. Pat. No. 4,402,950, i.e. a DNA non enveloped virus and therefore would not be led to search a further component deactivating a DNA enveloped virus. Even, if the man skilled in the art would be aware of the existence of U.S. Pat. No. 3,429,971, he would never use the component Trans-Geraniol in combination with carvone because column 3, table 2 second and third rows of U.S. Pat. No. 3,429,971 would dissuade him to combine both components because the man skilled in the art will learn that Trans-Geraniol does not have any curing effect (see table 2 of U.S. Pat. No. 3,429,971, namely the value zero cure).

In addition, the man skilled in the art would never find any indication in the prior art giving him any hint to use a composition containing carvone and Trans-Geraniol combined with at least one more component chosen among essential oils in a pharmaceutically effective concentration and selected from the list of components of claim 2 because the components listed in claim 2 are nor disclosed in U.S. Pat. No. 4,402,950, nor in U.S. Pat. No. 3,429,971, in combination.

The comparative tests listed in the present invention prove the above assertion. Even if the man skilled in the art would have, for an unknown reason, combined carvone with Trans-Geraniol for deactivating a DNA non enveloped virus, the comparative tests prove that no regression of lesions on the surface of the cervix have been observed, while for the synergetic composition of claim 1, 20%-100% of regression of lesions on the surface of the cervix have been observed. Consequently, there is a synergism between the combination of (+) carvone and (−) carvone and Trans-Geraniol and at least one more component chosen among essential oils in a pharmaceutically effective concentration of the present invention provoking an unexpected and surprising effect, i.e. 20%-100% of regression of lesions on the surface of the cervix.

Clinical and experimental pharmacology and physiology (2005) 32, pages 811-816 entitled “antiviral activities of extracts and selected pure constituents of ocimum basilicum” shows that purified components of ocimum basilicum were used to identify possible antiviral activities against human DNA viruses (HSV, ADV) and RNA viruses (CVB1, EV71). No activity was noted for carvone, cineole, beta-caryophylene, farnesol, fenchone, geraniol, beta-myrcene and alpha-thujone (it is to understand that no activity was noted for each component used alone). The difference between the present invention and this document is that the composition of the present invention is a synergetic combination of several compounds which proved having an unexpected antiviral effect.

Antiviral research 42 (1999) pages 219-226 is entitled “plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2” relates to protective efficacy in vivo in a mouse (see page 220 second column last paragraph) and a guinea pig model (see page 223 second column) of genital HSV-2 infection. At page 223 second column it is mentioned that infection in a guinea pig model, unlike in the mouse, does not result in death and more closely mimics the natural course of disease in humans. For these experiments, 0.1 ml of eugenol was instilled into the vaginal vault of female guinea pigs followed 20 seconds later by instillation of 0.1 ml of virus suspension containing 106 pfu of HSV-2 MS strain. Table 2 shows that treatment with eugenol immediately prior to intravaginal inoculation resulted in significant fewer animals developing symptomatic primary disease compared to PBS-treated controls. These data indicate that eugenol does have direct antiviral activity. The difference between the present invention and “Antiviral research 42 (1999) pages 219-226” is that in the present invention the novel synergetic composition is instilled after the viruses infected the human body in order to treat human diseases. It is obvious for a man skilled in the art that eugenol can be used as a prophylactic in vivo if it is instilled in a dosis of 0.1 ml prior to instillation of 0.1 ml of HSV-2 MS strain suspension in the vagina. The operating steps in the present invention are inversed comparing to those mentioned in the prior art document “Antiviral research 42 (1999) pages 219-226”. In addition, Eugenol in the present invention has the chemical formula “2-methoxy-4-prop-2-enylphenol” while page 223 first column second paragraph mentions eugenol as having the formula “4-hydroxy-3-methoxy-allylbenzene” which might be a different structural formula than that of the present invention.

Phytotherapy research 14, pages 495-500 (2000) entitled “In vitro and in vivo activity of Eugenol on human herpesvirus” mentions that Eugenol-acyclovir combinations synergistically inhibited herpesvirus replication in vitro and that topical application of eugenol delayed the development of herpesvirus induced keratitis in a mouse. Eugenol in the present invention has the chemical formula “2-methoxy-4-prop-2-enylphenol”, while in the abstract of this document eugenol is mentioned as having the formula “4-hydroxy-3-methoxy-allylbenzene” which might be a different structural formula than that of the present invention. The difference between the present invention and this document is that the composition of the present invention is a synergetic combination of several different compounds (other than the combination Eugenol-acyclovir) which proved having an unexpected antiviral effect. In addition, page 497 second column last paragraph bridging with page 498 first column first paragraph discloses that different dilutions of eugenol were instilled in each eye of mice before virus inoculation; after infection mice received the corresponding treatment three times a day and during 5 days (i.e. 15 applications). The difference between the present invention and this document is that in the present invention the novel synergetic composition is instilled after the viruses infected the human body in order to treat human diseases. The operating steps in the present invention are inversed comparing to those mentioned in this prior art document. It is obvious for a man skilled in the art that eugenol can be used as a prophylactic in vivo if it is instilled in a dosis of 1 mg/ml or 0.5 mg/ml prior to virus inoculation.

Natural Product Communications, 2008 vol. 3, No 7, 1085-1088 entitled “investigation of anticancer and antiviral properties of selected aroma samples” discloses that synthetic nerolidol samples at concentrations less than 5 microMolar have anti-tumor effects in vitro. Antiviral studies were performed to investigate inhibitory effects of the compounds on mouse polyomavirus (MPyV) propagation in 3T6 cells. 3T6 cells were washed with DMEM and incubated with virus inoculum for 1 h at 37° C. After that, DMEM supplemented with FBS and containing compounds to be analyzed was added. The difference between the present invention and this document is that the composition of the present invention is a synergetic combination of several different compounds which proved having an unexpected antiviral effect on humans. Results of tests on human beings cannot be compared to in vitro tests.

General Comments on the Prior Art Documents:

Any prior art document dealing with in vitro tests cannot be considered pertinent because the compositions of the present invention have been tested in vivo i.e. on animals or on human beings and it is well known by a man skilled in the art that test results can strongly differ if they are performed in an in vitro versus an in vivo environment. An extensive literature search did not find out any evidence or correlation that even if a composition is active in vitro, a man skilled in the art could deduct that the same composition would also be active in vivo. We also refer to Antiviral research 42 (1999) pages 219-226 is entitled “plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2” (already previously mentioned) where it is stated at page 224 first column “Several compounds showed activity in vitro but performed poorly in vivo. This failure of in vitro results to predict in vivo efficacy has previously been noted by zeitlin et al. (1997)”. This is even proven in the table of this document.

SUMMARY OF THE INVENTION

Compositions for use in treatment and prevention of diseases caused by DNA enveloped, DNA non-enveloped, RNA enveloped, RNA non-enveloped viruses are presented. The technical effect of the present invention is to prevent viruses merging with the host cell(s) by interfering with the viral lipid envelope.

The technical problem to be solved is to prevent the multiplication of the viruses in animals and human beings and therefore curing diseased animals or human beings.

To solve the problem, the present invention provides a synergetic composition according to the claims.

It is inferred from some scientific studies that non-enveloped viruses acquire a lipid envelope from the host and as the composition of the present invention interferes with this triglyceride envelope and the envelope of enveloped viruses, it can be declared that the composition of the present invention will de-activate all types of viruses in vivo within animals or human beings.

Following are the most common viruses that can be de-activated with the compositions according to the present invention.

As the mode of action of the invention is non-specific, the virus species and serotype is irrelevant.

The person skilled in the art knows that all viruses are classified into 4 major groups consisting of DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.

All compositions of the present invention are pharmaceutical compositions in a pharmaceutically effective weight percentage which can treat animal and/or human diseases.

List of Diseases: List E:

The compositions of the present invention are used for treating and preventing a disease related to one of the above mentioned viral groups as well as on diseases selected from the non exhaustive group consisting in: (broncho)-pneumonia, 3 day fever exanthema, acute and chronic hepatitis, acute fever, acute gastroenteritis caused by strains such as Desert Shield Lordsdale Mexico Norwalk Hawaii Snow Mountain Southampton virus, acute gastroenteritis caused by strains such as Houston/86 Houston/90 London 29845 Manchester Parkville Sapporo virus, acute hepatitis, acute respiratory distress syndrome, AIDS, anogenital mucosa, Argentine hemorrhagic fever, arthralgia, avian flu, Bolivian hemorrhagic fever, Brazilian hemorrhagic fever, chickenpox, chronic hepatitis, coma, common cold infection, common cold symptoms, congenital infection, conjunctivitis, contagious eethyma, contagious pustular dermatitis, cornea, Creutzfeldt-Jakob-Disease, cryptic enteric infection, cytomegaloviral mononucleosis, dengue hemorrhagic fever (DHF), dengue shock syndrome (DSS), diarrhea, eczema, eczema herpaticum, encephalitis, encephalopathy, enteritis, epidemic nephropathy, epidemic polyarthritis and exanthema, epidermodysplasia veruciformis, Epstein-Barr virus infection, exanthema, exanthema in children, Fatal familial insomnia, febrile encephalitis, febrile illness, fever, formerly Human echovirus 22 23, gastroenteritis, gastrointestinal infections intracytoplasmic inclusion bodies, genital tract infections, haemolytic crisis in people with sickle cell disease, headaches, hemorrhagic fever, hemorrhagic fever w renal syndrome, herpetic encephalitis, Hodgkin's disease, Human coxsackievirus, Human coxsackievirus B1-6, Human echovirus 1-7 9 11-21 24-27 29-33, Human enterovirus 69, Human enterovirus 71 (hand foot and mouth disease), Human hepatitis virus A (HHAV), Human poliovirus, Human rhinovirus 1 2 7 9 11 15 16 21 29 36 39 49 50 58 62 65 85 89 hyperacute respiratory disease, Human rhinovirus 3 14 72, hyperacute respiratory disease, immune deficiency syndrome, infantile diarrhea, Infection with any dengue serotype (1-4), infectious mononucleosis, joint pain, Kaposi's sarcoma, keratoconjunctivitis, Kuru, lesions of coutanous sites, leucopoenia, liver cirrhosis, lower respiratory tract infection, lymphadenopathy, maculopapular rash, malignant tissue, measles, meningitis, mononucleosis (kissing disease), mumps, muscle pains, myocarditis, nephropathy, nephropathy in transplant patients, numbness, old world, opportunistic infection, oral infections, oral mucosa, orchitis, pancreatitis, pandemics, papilloma, paralysis, persistent infection of the kidney, persistent infections, persistent lymphopathy, pharyngeal conjunctivitis, pneumonia, primary hepatocellular carcinoma, pulmonary syndrome, rabies, rash, recurrent epidemics of respiratory disease, respiratory disease, respiratory illness, Roseola infantum, sarcoma, scarring, sever chills arthralgia, severe acute respiratory syndrome, severe encephalitis, shingles, sixth disease, skin and mucous membrane lesions, slim disease, sore throat, subacute sclerosing panencephalitis, superinfection with Deltavirus, ulceration, upper respiratory tract illness, Venezuelan hemorrhagic fever, vesicular pharyngitis, vesicular stomatitis with exanthema, viral polyarthritis and rush, viral warts, watery diarrhea, weakness, zoonotic, zoster, metaplasia, dysplasia, anaplasia, desmoplasia, carcinoma in situ, flu (influenza), invasive carcinoma, as well as any disease directly or indirectly related to the above mentioned viruses.

Examples of Viruses:

Information about the viruses can be found on internet at the following link: http://www.ncbi.nlm.nih.gov/ICTVdb/Ictv/ICD-10.htm

A non exhaustive list of viruses and their species which can be deactivated and therefore prevented from multiplication by the compositions of the present invention is as follows:

Abadina virus (Reoviridae), Abelson murine leukemia virus (Retroviridae), Abras virus (Bunyaviridae), Absettarov virus (Flaviviridae), Abu Hammad virus (Bunyaviridae), Abu Mina virus (Bunyaviridae), Acado virus (Reoviridae), Acara virus (Bunyaviridae), Acciptrid herpesvirus (Herpesviridae), Acheta domestica densovirus (Parvoviridae), Acrobasis zelleri entomopoxvirus (Poxyiridae), Adelaide River virus (Rhabdoviridae), Adeno-associated virus (Parvoviridae), Aedes aegypti densovirus (Parvoviridae), Aedes aegypti entomopoxvirus (Poxyiridae), Aedes albopictus densovirus (Parvoviridae), Aedes pseudoscutellaris densovirus (Parvoviridae), African green monkey cytomegalovirus (Herpesviridae), African green monkey HHV-like virus (Herpesviridae), African green monkey polyomavirus (Papovaviridae), African horse sickness viruses (Reoviridae), African swine fever virus, African swine fever-like viruses, AG-virus (Bunyaviridae), AG-virus, (Bunyaviridae), Agaricus bisporus virus, Aguacate virus (Bunyaviridae), Ahlum water-borne virus (Tombusviridae), Aino virus (Bunyaviridae), Akabane virus (Bunyaviridae), AKR (endogenous) murine leukemia virus (Retroviridae), Alajuela virus (Bunyaviridae), Alcelaphine herpesvirus (Herpesviridae), Alenquer virus (Bunyaviridae), Aleutian disease virus (Parvoviridae), Aleutian mink disease virus (Parvoviridae), Alfuy virus (Flaviviridae), Allerton virus (Herpesviridae), Allitrich herpesvirus (Herpesviridae), Allomyces arbuscula virus, Almeirim virus (Reoviridae), Almpiwar virus (Rhabdoviridae), Altamira virus, (Reoviridae), Amapari virus (Arenaviridae), American ground squirrel herpesvirus, (Herpesviridae), Amsacta moorei entomopoxvirus (Poxyiridae), Amyelosis chronic stunt virus (Caliciviridae), Ananindeua virus (Bunyaviridae), Anatid herpesvirus (Herpesviridae), Andasibe virus (Reoviridae), Anhanga virus (Bunyaviridae), Anhembi virus (Bunyaviridae), Anomala cuprea entomopoxvirus (Poxyiridae), Anopheles A virus (Bunyaviridae), Anopheles virus (Bunyaviridae), Antequera virus (Bunyaviridae), Aotine herpesvirus (Herpesviridae), Apeu virus (Bunyaviridae), Aphodius tasmaniae entomopoxvirus (Poxyiridae), Apoi virus (Flaviviridae), Aransas Bay virus (Bunyaviridae), Arbia virus (Bunyaviridae), Arboledas virus (Bunyaviridae), Arbroath virus (Reoviridae), Argentine turtle herpesvirus (Herpesviridae), Arkonam virus (Reoviridae), Aroa virus (Flaviviridae), Arphia conspersa entomopoxvirus (Poxyiridae), Aruac virus (Rhabdoviridae), Arumowot virus (Bunyaviridae), Asinine herpesvirus (Herpesviridae), Atlantic cod ulcus syndrome virus (Rhabodoviridae), Atlantic salmon reovirus Australia (Reoviridae), Atlantic salmon reovirus Canada (Reoviridae), Atlantic salmon reovirus USA (Reoviridae), Atropa belladorma virus (Rhabdoviridae), Aucuba bacilliform virus, Badnavirus, Aujeszky's disease virus (Herpesviridae), Aura virus (Togaviridae), Auzduk disease virus (Poxyiridae), Avalon virus (Bunyaviridae), Avian adeno-associated virus (Parvoviridae), Avian carcinoma, Mill Hill virus (Retroviridae), Avian encephalomyelitis virus (Picornaviridae), Avian infectious bronchitis virus (Coronaviridae), Avian leukosis virus-RSA (Retroviridae), Avian myeloblastosis virus (Retroviridae), Avian myelocytomatosis virus (Retroviridae), Avian nephrites virus (Picornaviridae), Avian paramyxovirus (Paramyxoviridae), Avian reovirus (Reoviridae), B virus (Parvoviridae), B-lymphotropic papovavirus (Papovaviridae), Babahoya virus (Bunyaviridae), Babanki virus (Togaviridae), Baboon herpesvirus (Herpesviridae), Baboon polyomavirus (Papovaviridae), Bagaza virus (Flaviviridae), Bahia Grande virus (Rhabdoviridae), Bahig virus (Bunyaviridae), Bakau virus (Bunyaviridae), Baku virus (Reoviridae), Bald eagle herpesvirus (Herpesviridae), Bandia virus (Bunyaviridae), Bangoran virus (Rhabdoviridae), Bangui virus (Bunyaviridae), Banzi virus (Flaviviridae), Barmah Forest virus (Togaviridae), Barranqueras virus (Bunyaviridae), Barur virus (Rhabdoviridae), Batai virus (Bunyaviridae), Batarna virus (Bunyaviridae), Balken virus (Bunyaviridae), Bauline virus (Reoviridae), Beak and feather disease virus (Circoviridae), BeAn virus (Rhabdoviridae), BeAr virus (Bunyaviridae), Bebaru virus (Togaviridae), Belem virus (Bunyaviridae), Belmont virus ((Bunyaviridae)), Belterra virus (Bunyaviridae), Benevides virus (Bunyaviridae), Benfica virus (Bunyaviridae), Berne virus, (Coronaviridae), Berrimah virus (Rhabdoviridae), Bertioga virus (Bunyaviridae), Bhanja virus (Bunyaviridae), Bimbo virus (Rhabdoviridae), Bimiti virus (Bunyaviridae), Birao virus (Bunyaviridae), BivensArm virus (Rhabdoviridae), BK virus (Papovaviridae), Bluetongue viruses (Reoviridae), Bobaya virus (Bunyaviridae), Bobia virus (Bunyaviridae), Bobwhite quail herpesvirus (Herpesviridae), Boid herpesvirus (Herpesviridae), Bombyx mori densovirus (Parvoviridae), Boolarra virus (Nodaviridae), Boraceia virus (Bunyaviridae), Border disease virus (Flaviviridae), Boma disease virus, Botambi virus (Bunyaviridae), Boteke virus, (Rhabdoviridae), Bouboui virus (Flaviviridae), Bovine adeno-associated virus (Parvoviridae), Bovine adenoviruses (Adenoviridae), Bovine astrovirus (Astroviridae), Bovine coronavirus (Coronaviridae), Bovine diarrhea virus (Flaviviridae), Bovine encephalitis herpesvirus (Herpesviridae), Bovine enteric calicivirus (Caliciviridae), Bovine enterovirus (Picornaviridae), Bovine ephemeral fever virus (Rhabdoviridae), Bovine herpesvirus (Herpesviridae), Bovine immunodeficiency virus (Retroviridae), Bovine leukemia virus (Retroviridae), Bovine mamillitis virus (Herpesviridae), Bovine papillomavirus (Papovaviridae), Bovine papular stomatitis virus (Poxyiridae), Bovine parainfluenza virus (Paramyxoviridae), Bovine parvovirus (Parvoviridae), Bovine polyomavirus (Papovaviridae), Bovine respiratory syncytial virus (Paramyxoviridae), Bovine rhinovirus (Picornaviridae), Bovine syncytial virus (Retroviridae), Bozo virus (Bunyaviridae), Broadhaven virus (Reoviridae), Bruconha virus (Bunyaviridae), Brus Laguna virus (Bunyaviridae), Budgerigar fledgling disease virus (Papovaviridae), Buenaventura virus (Bunyaviridae), Buffalopox virus (Poxyiridae), Buggy Creek virus (Togaviridae), Bujaru virus (Bunyaviridae), Bukalasa bat virus (Flaviviridae), Bunyamwera virus (Bunyaviridae), Bunyip creek virus (Reoviridae), Bushbush virus (Bunyaviridae), Bussuquara virus (Flaviviridae), Bwamba virus (Bunyaviridae), Cache Valley virus (Bunyaviridae), Cacipacore virus (Flaviviridae), Caddo Canyon virus (Bunyaviridae), Caimito virus (Bunyaviridae), Calchaqui virus (Rhabdoviridae), California encephalitis virus (Bunyaviridae), California harbor sealpox virus (Poxyiridae), Callistephus chinensis chlorosis virus (Rhabdoviridae), Callitrichine herpesvirus (Herpesviridae), Camel contagious eethyma virus (Poxyiridae), Camelpox virus (Poxyiridae), Camptochironomus tentans entomopoxvirus (Poxyiridae), Cananeia virus (Bunyaviridae), Canarypox virus (Poxyiridae), Candiru virus (Bunyaviridae), Canid herpesvirus (Herpesviridae), Caninde virus (Reoviridae), Canine adeno-associated virus (Parvoviridae), Canine adenovirus (Adenoviridae), Canine calicivirus (Caliciviridae), Canine coronavirus (Coronaviridae), Canine distemper virus (Paramyxoviridae), Canine herpesvirus (Herpesviridae), Canine minute virus (Parvoviridae), Canine oral papillomavirus (Papovaviridae), Canine parvovirus (Parvoviridae), Canna yellow mottle virus (Badnavirus), Cape Wrath virus (Reoviridae), Capim virus (Bunyaviridae), Caprine adenovirus (Adenoviridae), Caprine arthritis encephalitis virus (Retroviridae), Caprine herpesvirus (Herpesviridae), Capuchin herpesvirus AL-(Herpesviridae), Capuchin herpesvirus AP-(Herpesviridae), Carajas virus (Rhabdoviridae), Caraparu virus (Bunyaviridae), Carey Island virus (Flaviviridae), Casphalia extranea densovirus (Parvoviridae), Catu virus (Bunyaviridae), Caviid herpesvirus ((Herpesviridae)), CbaAr virus (Bunyaviridae), Cebine herpesvirus (Herpesviridae), Cercopithecine herpesvirus (Herpesviridae), Cervid herpesvirus (Herpesviridae), CG-virus (Bunyaviridae), Chaco virus (Rhabdoviridae), Chagres virus (Bunyaviridae), Chamois contagious ecthvma virus (Poxyiridae), Chandipura virus (Rhabdoviridae), Changuinola virus (Reoviridae), Charleville virus (Rhabdoviridae), Chelonid herpesvirus (Herpesviridae), Chelonid herpesvirus (Herpesvirzdae), Chelonid herpesvirus (Herpesviridae), Chenuda virus (Reoviridae), Chick syncytial virus (Retroviridae), Chicken anemia virus (Circoviridae), Chicken parvovirus (Paruoviridae), Chikungunya virus (Togaviridae), Chilibre virus (Bunyaviridae), Chim virus (Bunyaviridae), Chimpanzee herpesvirus (Herpesviridae), Chironomus attenuatus entomopoxvirus (Poxyiridae), Chironomus luridus entomopoxvirus (Poxyiridae), Chironomus plumosus erltomopoxvirus (Poxyiridae), Chobar Gorge virus (Reoviridae), Choristoneura biennis entomopoxvirus (Poxyiridae), Choristoneura conflicta entomopoxvirus (Poxyiridae), Choristoneura diversuma entomopoxvirus (Poxyiridae), Chorizagrotis auxiliars entomopoxvirus (Poxyiridae), Chub reovirus Germany (Reoviridae), Ciconiid herpesvirus (Herpesviridae), Clo Mor virus (Bunyaviridae), CoAr-virus (Bunyaviridae), Coastal Plains virus (Rhabdoviridae), Cocal virus (Rhabdoviridae), Coital exanthema virus (Herpesviridae), ColAn-virus (Bunyaviridae), Colocasia bobone disease virus, (Rhabdoviridae), Colorado tick fever virus, (Reoviridae), Columbia SK virus, (Picornaviridae), Columbid herpesvirus, (Herpesviridae), Connecticut virus, (Rhabdoviridae), Contagious eethyma virus, (Poxyiridae), Contagious pustular dermatitis virus, (Poxyiridae), Corfu virus, (Bunyaviridae), Corriparta virus, (Reoviridae), Cotia virus, (Poxyiridae), Cowpox virus, (Poxyiridae), Crimean-Congo hemorrhagic fever virus, (Bunyaviridae), CSIRO village virus, (Reoviridae), Cynara virus, (Rhabdoviridae), Cyprinid herpesvirus, (Herpesviridae), Dabakala virus, (Bunyaviridae), D'Aguilar virus, (Reoviridae), Dakar bat virus, (Flaviviridae), DakArk virus, (Rhabdoviridae), Deer papillomavirus, (Papovaviridae), Demodema boranensis entomopoxvirus, (Poxyiridae), Dengue virus, (Flaviviridae), Dengue virus group, (Flaviviridae), Dependovirus, (Parvoviridae), Dera Ghazi Khan virus, (Bunyaviridae), Dera Ghazi Khan virus Group, (Bunyaviridae), Dermolepida albohirtum entomopoxvirus, (Poxyiridae), Dhori virus, (Orthomyxoviridae), Diatraea saccharalis densovirus, (Parvoviridae), Dobrava-Belgrade virus, (Bunyaviridae), Dolphin distemper virus, (Paramyxoviridae), Dolphinpox virus, (Poxyiridae), Douglas virus, (Bunyaviridae), Drosophila C virus, (Picornaviridae), Dry Tortugas virus, (Bunyaviridae), duck adenovirus, (Adenoviridae), Duck adenovirus, (Adenoviridae), Duck astrovirus, (Astroviridae), Duck hepatitis B virus, (Hepadnaviridae), Duck plague herpesvirus syn. anatid herpesvirus, (Herpesviridae), Dugbe virus, (Bunyaviridae), Duvenhage virus, (Rhabdoviridae), Eastern equine encephalitis virus, (Togaviridae), Ebola virus Filoviridae, Echinochloa hoja blanca virus; Genus Tenuivirus, Echinochloa ragged stunt virus, (Reoviridae), ectromelia virus, (Poxyiridae), Edge Hill virus, (Flaviviridae), Egtved virus syn. viral hemorrhagic septicemia virus, (Rhabdoviridae), Elapid herpesvirus, (Herpesviridae), Elephant loxondontal herpesvirus, (Herpesviridae), Elephant papillomavirus, (Papovaviridae), Elephantid herpesvirus, (Herpesviridae), Ellidaey virus, (Reoviridae), Embu virus, (Poxyiridae), Encephalomyocarditis virus, (Picornaviridae), Enseada virus, (Bunyaviridae), Entamoeba virus, (Rhabdoviridae), Entebbe bat virus, (Flaviviridae), Epizootic hemorrhagic disease viruses, (Reoviridae), Epstein-Barr virus, (Herpesviridae), Equid herpesvirus, (Herpesviridae), Equid herpesvirus, (Nerpesviridae), Equid herpesvirus, (Herpesviridae), Equine abortion herpesvirus, (Herpesviridae), Equine adeno-associated virus, (Parvoviridae), Equine adenovirus, (Adenoviridae), Equine arteritis virus, (Arterivirus), Equine cytomegalovirus, (Herpesviridae), Equine encephalosis viruses, (Reoviridae), Equine herpesvirus, (Herpesviridae), Equine infectious anemia virus, (Retroviridae), Equine papillomavirus, (Papovaviridae), Equine rhinopneumonitis virus, (Herpesviridae), Equine rhinovirus, (Picornaviridae), Eret-virus, (Bunyaviridae), Erinaceid herpesvirus, (Herpesviridae), Erve virus, (Bunyaviridae), Erysimum latent virus, Tymovirus, Esocid herpesvirus, (Herpesviridae), Essaouira virus, (Reoviridae), Estero Real virus, (Bunyaviridae), Eubenangee virus, (Reoviridae), Euonymus fasciation virus, (Rhabdoviridae), European bat virus, (Rhabdoviridae), European brown hare syndrome virus, (Caliciviridae), European elk papillomavirus, (Papovaviridae), European ground squirrel cytomegalovirus, (Herpesviridae), European hedgehog herpesvirus, (Herpesviridae), Everglades virus, (Togaviridae), Eyach virus, (Reoviridae), Facey's Paddock virus, (Bunyaviridae), Falcon inclusion body disease, (Herpesviridae), Falconid herpesvirus, (Herpesviridae), Farallon virus, (Bunyaviridae), Felid herpesvirus, (Herpesviridae), Feline calicivirus, (Caliciviridae), Feline herpesvirus, (Herpesviridae), Feline immunodeficiency virus, (Retroviridae), Feline infectious peritonitis virus, (Coronaviridae), Feline leukemia virus, (Retroviridae), Feline parlleukopenia virus, (Parvoviridae), Feline parvovirus, (Parvoviridae), Feline syncytial virus, (Retroviridae), Feline viral rhinotracheitis virus, (Herpesviridae), Fetal rhesus kidney virus, (Papovaviridae), Field mouse herpesvirus, (Herpesviridae), Figulus subleavis entomopoxvirus, (Poxyiridae), Fiji disease virus, (Reoviridae), Fin V-virus, (Bunyaviridae), Finkel-Biskis-Jinkins murine sarcoma virus, (Retroviridae), Flanders virus, (Rhabdoviridae), Flexal virus, (Arenaviridae), Flock house virus, Nodaviridae, Foot-and-mouth disease virus A, (Picornaviridae), Foot-and-mouth disease virus ASIA, (Picornaviridae), Foot-and-mouth disease virus, (Picornaviridae), Forecariah virus, (Bunyaviridae), Fort Morgan virus, (Togaviridae), Fort Sherman virus, (Bunyaviridae), Foula virus, (Reoviridae), Fowl adenoviruses, (Adenoviridae), Fowl calicivirus, (Caliciviridae), Fowlpox virus, (Poxyiridae), Fraser Point virus, (Bunyaviridae), Friend murine leukemia virus, (Retroviridae), Frijoles virus, (Bunyaviridae), Frog herpesvirus, (Herpesviridae), Fromede virus, (Reoviridae), Fujinami sarcoma virus, (Retroviridae), Fukuoka virus, (Rhabdoviridae), Gabek Forest virus, (Bunyaviridae), Gadget's Gully virus, (Flaviviridae), Galleria mellonella densovirus, (Parvoviridae), Gallid herpesvirus, (Herpesviridae), Gamboa virus, (Bunyaviridae), Gan Gan virus, (Bunyaviridae), Garba virus, (Rhabdoviridae), Gardner-Arnstein feline sarcoma virus, (Retroviridae), Geochelone carbonaria herpesvirus, (Herpesviridae), Geochelone chilensis herpesvirus, (Herpesviridae), Geotrupes sylvaticus entomopoxvirus, (Poxyiridae), Gerbera symptomless virus, (Rhabdoviridae), Germiston virus, (Bunyaviridae), Getah virus, (Togaviridae), Gibbon ape leukemia virus, (Retroviridae), Ginger chlorotic fleckvirus, Sobemovirus, Glycine mottle virus, Tombusviridae, Goat herpesvirus, (Herpesviridae), Goatpox virus, (Poxyiridae), Goeldichironomus holoprasimus entomopoxvirus, (Poxyiridae), Golden shiner reovirus, (Reoviridae), Gomoka virus, (Reoviridae), Gomphrena virus, (Rhabdoviridae), Gonometa virus, (Picornaviridae), Goose adenoviruses, (Adenoviridae), Goose parvovirus, (Parvoviridae), Gordil virus, (Bunyaviridae), Gorilla herpesvirus, (Herpesviridae), Gossas virus, (Rhabdoviridae), Grand Arbaud virus, (Bunyaviridae), Gray Lodge virus, (Rhabdoviridae), Gray patch disease agent of green sea turtle, (Herpesviridae), Great Island virus, (Reoviridae), Great Saltee Island virus, (Reoviridae), Great Saltee virus, (Bunyaviridae), Green iguana herpesvirus, (Herpesviridae), Green lizard herpesvirus, (Herpesviridae), Grey kangaroopox virus, (Poxyiridae), Grimsey virus, (Reoviridae), Ground squirrel hepatitis B virus, (Hepadnaviridae), GroupA-K rotaviruses, (Reoviridae), Gruid herpesvirus, (Herpesviridae), GUU-virus, (Bunyaviridae), Guajara virus, (Bunyaviridae), Guama virus, (Bunyaviridae), Guanarito virus, (Arenaviridae), Guaratuba virus, (Bunyaviridae), Guaroa virus, (Bunyaviridae), Guinea pig cytomegalovirus, (Herpesviridae), Guinea pig herpesvirus, (Herpesviridae), Guinea pig type C oncovirus, (Retroviridae), Gumbo Limbo virus, (Bunyaviridae), Gurupi virus, (Reoviridae), H-virus, (Parvoviridae), H virus, (Bunyaviridae), Hamster herpesvirus, (Herpesviridae), Hamster polyomavirus, (Papovaviridae), Hantaan virus, (Bunyaviridae), Hanzalova virus, (Flaviviridae), Hardy-Zuckerman feline sarcoma virus, (Retroviridae), Hare fibroma virus, (Poxyiridae), Hart Park virus, (Rhabdoviridae), Hartebeest herpesvirus, (Herpesviridae), Harvey murine sarcoma virus, (Retroviridae), Hazara virus, (Bunyaviridae), HB virus, (Parvoviridae), Hepatitis virus, (Picornaviridae), Hepatitis virus, (Hepadnaviridae), Hepatitis virus, (Flaviviridae), Herpesvirus M, (Herpesviridae), Herpesvirus papio, (Herpesviridae), Herpesvirus platyrrhinae type, (Herpesviridae), Herpesvirus pottos, (Herpesviridae), Herpesvirus saimiri, (Herpesviridae), Herpesvirus salmonis, (Herpesviridae), Herpesvirus sanguinus, (Herpesviridae), Herpesvirus scophthalmus, (Herpesviridae), Herpesvirus sylvilagus, (Herpesviridae), Herpesvirus T, (Herpesviridae), Herpesvirus tarnarinus, (Herpesviridae), Highlands J virus, (Togaviridae), Hirame rhabdovirus, (Rhabdoviridae), Hog cholera virus, (Flaviviridae), HoJo virus, (Bunyaviridae), Hepatitis delta virus, Satellites, Deltavirus, Hsiung Kaplow herpesvirus, (Herpesviridae), Hepatitis E virus, (Caliciviridae), Hepatopancreatic parvo-like virus of shrimps, (Parvoviridae), Heron hepatitis B virus, (Hepadnaviridae), Herpes ateles, (Herpesviridae), Herpes simiae virus, (Herpesviridae), Herpes simplex virus, (Herpesviridae), Herpes virus B, (Herpesviridae), Herpesvirus aotus, (Herpesviridae), Herpesvirus ateles strain, (Herpesviridae), Herpesvirus cuniculi, (Herpesviridae), Herpesvirus cyclopsis, (Herpesviridae), Huacho virus, (Reoviridae), Hughes virus, (Bunyaviridae), Human adenoviruses, (Adenoviridae), Human astrovirus, (Astroviridae), Human calicivirus, (Caliciviridae), Human caliciviruses, (Caliciviridae), Human coronavirus E, (Coronaviridae), Human coronavirus OC, (Coronaviridae), Human coxsackievirus, (Picornaviridae), Human cytomegalovirus, (Herpesviridae), Human echovirus, (Picornaviridae), Human enterovirus, (Picornaviridae), Human foamy virus, (Retroviridae), Human herpesvirus, (Herpesviridae), Human herpesvirus, Nerpesviridae, Human herpesvirus, (Herpesviridae), Human immunodeficiency virus, (Retroviridae), Human papillomavirus, (Papovaviridae), Human parainfluenza virus, (Paramyxoviridae), Human poliovirus, (Picornaviridae), Human respiratory syncytial virus, (Paramyxoviridae), Human rhinovirus, (Picornaviridae), Human spumavirus, (Retroviridae), Human T-lymphotropic virus, (Retroviridae), Humpty Doo virus, (Rhabdoviridae), HV-virus, (Bunyaviridae), Hypr virus, (Flaviviridae), Laco virus, (Bunyaviridae), lbaraki virus, (Reoviridae), Icoaraci virus, (Bunyaviridae), Ictalurid herpesvirus, (Herpesviridae), Leri virus, (Reoviridae), Ife virus, (Reoviridae), Iguanid herpesvirus, (Herpesviridae), Ilesha virus, (Bunyaviridae), Ilheus virus, (Flaviviridae), Inclusion body rhinitis virus, (Herpesviridae), Infectious bovine rhinotracheitis virus, (Herpesviridae), Infectious bursal disease virus, Birnaviridae, Infectious hematopoietic necrosis virus, (Rhabdoviridae), Infectious laryngotracheitis virus, (Herpesviridae), Infectious pancreatic necrosis virus, Birnavirzdae, InfluenzaA virus (A/PR//(HN), (Orthomyxoviridae), Influenza B virus (B/Lee/), (Orthomyxoviridae), Influenza C virus (C/California/), (Orthomyxoviridae), Ingwavuma virus, (Bunyaviridae), Inini virus, (Bunyaviridae), Inkoo virus, (Bunyaviridae), Inner Frame virus, (Reoviridae), Ippy virus, (Arenaviridae), Irituia virus, (Reoviridae), Isfahan virus, (Rhabdoviridae), Israel turkey meningoencephalitis virus, (Flaviviridae), Issyk-Kul virus, (Bunyaviridae), Itaituba virus, (Bunyaviridae), Itaporanga virus, (Bunyaviridae), Itaqui virus, (Bunyaviridae), Itimirirn virus, (Bunyaviridae), Itupiranga virus, (Reoviridae), Jaagsiekte virus, (Retroviridae), Jacareacanga virus, (Reoviridae), Jamanxi virus, (Reoviridae), Jamestown Canyon virus, (Bunyaviridae), Japanaut virus, (Reoviridae), Japanese encephalitis virus, (Flaviviridae), Jari virus, (Reoviridae), JC virus, (Papovaviridae), Joa virus, (Bunyaviridae), Joinjakaka virus, (Rhabdoviridae), Juan Diaz virus, (Bunyaviridae), Jugra virus, (Flaviviridae), Juncopox virus, (Poxyiridae), Junin virus, (Arenaviridae), Junonia coenia densovirus, (Parvoviridae), Jurona virus, (Rhabdoviridae), Jutiapa virus, (Flaviviridae), K virus, (Papovaviridae), K virus, (Bunyaviridae), Kachemak Bay virus, (Bunyaviridae), Kadarn virus, (Flaviviridae), Kaeng Khoi virus, (Bunyaviridae), Kaikalur virus, (Bunyaviridae), Kaki virus, (Bunyaviridae), Kaisodi virus, (Bunyaviridae), Kala Iris virus, (Reoviridae), Kamese virus, (Rhabdoviridae), Karnmavanpettai virus, (Reoviridae), Kannamangalam virus, (Rhabdoviridae), Kao Shuan virus, (Bunyaviridae), Karimabad virus, (Bunyaviridae), Karshi virus, (Flaviviridae), Kasba virus, (Reoviridae), Kasokero virus, (Bunyaviridae), Kedougou virus, (Flaviviridae), Kemerovo virus, (Reoviridae), Kenai virus, (Reoviridae), Kennedya virus Y, Potyviridae, Kern Canyon Yirus, (Rhabdoviridae), Ketapang virus, (Bunyaviridae), Keterah virus, (Bunyaviridae), Keuraliba virus, (Rhabdoviridae), Keystone virus, (Bunyaviridae), Kharagysh virus, (Reoviridae), Khasan virus, (Bunyaviridae), Kilham rat virus, (Parvoviridae), Kimberley virus, (Rhabdoviridae), Kindia virus, (Reoviridae), Kinkajou herpesvirus, (Herpesviridae), Kirsten murine sarcoma virus, (Retroviridae), Kismayo virus, (Bunyaviridae), Klamath virus, (Rhabdoviridae), Kokobera virus, (Flaviviridae), Kolongo virus, (Rhabdoviridae), Koolpinyah virus, (Rhabdoviridae), Koongol virus, (Bunyaviridae), Kotonkan virus, (Rhabdoviridae), Koutango virus, (Flaviviridae), Kowanyama virus, (Bunyaviridae), Kumlinge virus, (Flaviviridae), Kunjin virus, (Flaviviridae), Kwatta virus, (Rhabdoviridae), Kyzylagach virus, (Togaviridae), La Crosse virus, (Bunyaviridae), La Joya virus, (Rhabdoviridae), La-Piedad-Michoacan-Mexico virus, (Paramyxoviridae), Lacertid herpesvirus, (Herpesviridae), Lactate dehydrogenase-elevating virus, (Arterivirus), Lagos bat virus, (Rhabdoviridae), Lake Clarendon virus, (Reoviridae), Lake Victoria cormorant herpesvirus, (Herpesviridae), Langat virus, Ftaviviridae, Langur virus, (Retroviridae), Lanjan virus, (Bunyaviridae), Lapine parvovirus, (Parvoviridae), Las Maloyas virus, (Bunyaviridae), Lassa virus, (Arenaviridae), Lato river virus, (Tombusviridae), Le Dantec virus, (Rhabdoviridae), Leanyer virus, (Bunyaviridae), Lebombo virus, (Reoviridae), Lednice virus, (Bunyaviridae), Lee virus, (Bunyaviridae), Leporid herpesvirus, (Herpesviridae), Leucorrhinia dubia densovirus, (Parvoviridae), Lipovnik virus, (Reoviridae), Liverpool vervet monkey virus, (Herpesviridae), Llano Seco virus, (Reoviridae), Locusta migratona entomopoxvirus, (Poxyiridae), Lokem virus, (Bunyaviridae), Lone Star virus, (Bunyaviridae), Lorisine herpesvirus, (Herpesviridae), Louping ill virus, Flauiviridae, Lucke frog herpesvirus, (Herpesviridae), Lum virus, (Parvoviridae), Lukuni virus, (Bunyaviridae), Lumpy skin disease virus, (Poxyiridae), Lundy virus, (Reoviridae), Lymantria dubia densovirus, (Parvoviridae), Lymphocytic choriomeningitis virus, (Arenaviridae), Machupo virus, (Arenaviridae), Macropodid herpesvirus (Herpesviridae), Madrid virus, (Bunyaviridae), Maguari virus, (Bunyaviridae), Main Drain virus, (Bunyaviridae), Malakal virus, (Rhabdoviridae), Malignant catarrhal fever virus of European cattle, (Herpesviridae), Malpais Spring virus, (Rhabdoviridae), Malva silvestris virus, (Rhabdoviridae), Manawa virus, (Bunyaviridae), Manawatu virus, (Nodaviridae), Manitoba virus, (Rhabdoviridae), Manzanilla virus, (Bunyaviridae), Map turtle herpesvirus, (Herpesviridae), Mapputta virus, (Bunyaviridae), Maprik virus, (Bunyaviridae), Maraba virus, (Rhabdoviridae), Marburg virus, (Filoviridae), Marco virus, (Rhabdoviridae), Marek's disease herpesvirus, (Herpesviridae), Marituba virus, (Bunyaviridae), Marmodid herpesvirus, (Herpesviridae), Marmoset cytomegalovirus, (Herpesviridae), Marmoset herpesvirus, (Herpesviridae), Marmosetpox virus, (Poxyiridae), Marrakai virus, (Reoviridae), Mason-Pfizer monkey virus, (Retroviridae), Masou salmon reovirus, (Reoviridae), Matruh virus, (Bunyaviridae), Matucare virus, (Reoviridae), Mayaro virus, (Togaviridae), Mboke virus, (Bunyaviridae), Meaban virus, (Flaviviridae), Measles (Edmonston) virus, (Paramyxoviridae), Medical Lake macaque herpesvirus, (Herpesviridae), Melanoplus sanguinipes entomopoxvirus, (Poxyiridae), Melao virus, (Bunyaviridae), Meleagrid herpesvirus, (Herpesviridae), Melilotus latent virus, (Rhabdoviridae), Melolontha melolontha entomopoxvirus, (Poxyiridae), Mengovirus, (Picornaviridae), Mermet virus, (Bunyaviridae), Mice minute virus, (Parvoviridae), Mice pneumotropic virus, (Papovaviridae), Microtus pennsylvanicus herpesvirus, (Herpesviridae), Middelburg virus, (Togaviridae), Miller's nodule virus, (Poxyiridae), Mill Door virus, (Reoviridae), Minatitlan virus, (Bunyaviridae), Mink calicivirus, (Caliciviridae), Mink enteritis virus, (Parvoviridae), Minnal virus, (Reoviridae), Mirabilis mosaic virus, Caulimovirus, Mirim virus, (Bunyaviridae), Mitchell river virus, (Reoviridae), Mobala virus, (Arenaviridae), Modoc virus, (Flaviviridae), Moju virus, (Bunyaviridae), Mojui dos Campos virus, (Bunyaviridae), Mokola virus, (Rhabdoviridae), Molluscum contagiosum virus, (Poxyiridae), Molluscum-likepox virus, (Poxyiridae), Moloney murine sarcoma virus, (Retroviridae), Moloney virus, (Retroviridae), Monkey pox virus, (Poxyiridae), Mono Lake virus, (Reoviridae), Montana myotis leukoencephalitis virus, (Flaviviridae), Monte Dourado virus, (Reoviridae), Mopeia virus, (Arenaviridae), Moriche virus, (Bunyaviridae), Mosqueiro virus, (Rhabdoviridae), Mossuril virus, (Rhabdoviridae), Mount Elgon bat virus, (Rhabdoviridae), Mouse cytomegalovirus, (Herpesviridae), Mouse Elberfield virus, (Picornaviridae), Mouse herpesvirus strain, (Herpesviridae), Mouse mammary tumor virus, (Retroviridae), Mouse thymic herpesvirus, (Herpesviridae), Movar herpesvirus, (Herpesviridae), Mucambo virus, (Togaviridae), Mudjinbarry virus, (Reoviridae), Muir Springs virus, (Rhabdoviridae), Mule deerpox virus, (Poxyiridae), Multimammate mouse papillomavirus, (Papovaviridae), Mumps virus, (Paramyxoviridae), Murid herpesvirus, (Herpesviridae), Murine adenovirus, (Adenoviridae), Z murine adenovirus, (Adenoviridae), Murine hepatitis virus, (Coronaviridae), Murine herpesvirus, (Herpesviridae), Murine leukemia virus, (Retroviridae), Murine parainfluenza virus, (Paramyxoviridae), Murine poliovirus, (Picornaviridae), Murine polyomavirus, (Papovaviridae), Murray Valley encephalitis virus, (Flaviviridae), Murre virus, (Bunyaviridae), Murutucu virus, (Bunyaviridae), Mykines virus, (Reoviridae), Mynahpox virus, (Poxyiridae), Myxoma virus, (Poxyiridae), Nairobi sheep disease virus, (Bunyaviridae), Naranjal virus, (Flaviviridae), Nasoule virus, (Rhabdoviridae), Navarro virus, (Rhabdoviridae), Ndelle virus, (Reoviridae), Ndumu virus, (Togaviridae), Neckar river virus, (Tombusviridae), Negishi virus, (Flaviviridae), Nelson Bay virus, New Minto virus, (Rhabdoviridae), Newcastle disease virus, (Paramyxoviridae), Ngaingan virus, (Rhabdoviridae), Ngari virus, (Bunyaviridae), Ngoupe virus, (Reoviridae), Nile crocodilepox virus, (Poxyiridae), Nique virus, (Bunyaviridae), Nkolbisson virus, (Rhabdoviridae), Nola virus, (Bunyaviridae), North Clett virus, (Reoviridae), North End virus, (Reoviridae), Northern cereal mosaic virus, (Rhabdoviridae), Northern pike herpesvirus, (Herpesviridae), Northway virus, (Bunyaviridae), Norwalk virus, (Caliciviridae), Ntaya virus, (Flaviviridae), Nugget virus, (Reoviridae), Nyabira virus, (Reoviridae), Nyamanini virus, Unassigned, Nyando virus, (Bunyaviridae), Oak-Vale virus, (Rhabdoviridae), Obodhiang virus, (Rhabdoviridae), Oceanside virus, (Bunyaviridae), Ockelbo virus, (Togaviridae), Odrenisrou virus, (Bunyaviridae), Oedaleus senegalensis entomopoxvirus, (Poxyiridae), Oita virus, (Rhabdoviridae), Okhotskiy virus, (Reoviridae), Okola virus, (Bunyaviridae), Olifantsvlei virus, (Bunyaviridae), Omo virus, (Bunyaviridae), Omsk hemorrhagic fever virus, (Flaviviridae), Onchorhynchus masou herpesvirus, (Herpesviridae), O'nyong-nyong virus, (Togaviridae), Operophtera brurnata entomopoxvirus, (Poxyiridae), Orangutan herpesvirus, (Herpesviridae), Orf virus, (Poxyiridae), Oriboca virus, (Bunyaviridae), Oriximina virus, (Bunyaviridae), Oropouche virus, (Bunyaviridae), Orungo virus, (Reoviridae), Oryctes rhinoceros virus, Unassigned, Ossa virus, (Bunyaviridae), Ouango virus, (Rhabdoviridae), Oubi virus, (Bunyaviridae), Ourem virus, (Reoviridae), Ovine adeno-associated virus, (Parvoviridae), Ovine adenoviruses, (Adenoviridae), (Astroviridae), Ovine herpesvirus, (Herpesviridae), Ovine pulmonary adenocarcinoma virus, (Retroviridae), Owl hepatosplenitis herpesvirus, (Herpesviridae), P virus, (Bunyaviridae), Pacheco's disease virus, (Herpesviridae), Pacora virus, (Bunyaviridae), Pacui virus, (Bunyaviridae), Pahayokee virus, (Bunyaviridae), Palestina virus, (Bunyaviridae), Palyam virus, (Reoviridae), Pan herpesvirus, (Herpesviridae), Papio Epstein-Barr herpesvirus, (Herpesviridae), Para virus, (Bunyaviridae), Paramushir virus, (Bunyaviridae), Parana virus, (Arenaviridae), Parapoxvirus of red deer in New Zealand, (Poxyiridae), Paravaccinia virus, (Poxyiridae), Parma wallaby herpesvirus, (Herpesviridae), Paroo river virus, (Reoviridae), Parrot herpesvirus, (Herpesviridae), Parry Creek virus, (Rhabdoviridae), Pata virus, (Reoviridae), Patas monkey herpesvirus pH delta, (Herpesviridae), Pathum Thani virus, (Bunyaviridae), Patois virus, (Bunyaviridae), Peaton virus, (Bunyaviridae), Percid herpesvirus, (Herpesviridae), Perdicid herpesvirus, (Herpesviridae), Perinet virus, (Rhabdoviridae), Periplanata fuliginosa densovirus, (Parvoviridae), Peste-des-petits-ruminants virus, (Paramyxoviridae), Petevo virus, (Reoviridae), Phalacrocoracid herpesvirus, (Herpesviridae), Pheasant adenovirus, (Adenoviridae), Phnom-Penh bat virus, (Flaviviridae), Phocid herpesvirus, (Herpesviridae), Phocine (seal) distemper virus, (Paramyxoviridae), Pichinde virus, (Arenaviridae), Picola virus, (Reoviridae), Pieris rapae densovirus, (Parvoviridae), Pigeon herpesvirus, (Herpesviridae), Pigeonpox virus, (Poxyiridae), Badnavirus Piry virus, (Rhabdoviridae), Pisum virus, (Rhabdoviridae), Pixuna virus, (Togaviridae), Playas virus, (Bunyaviridae), Pleuronectid herpesvirus, (Nerpesviridae), Pneumonia virus of mice, (Paramyxoviridae), Pongine herpesvirus, (Herpesviridae), Pongola virus, (Bunyaviridae), Ponteves virus, (Bunyaviridae), Poovoot virus, (Reoviridae), Porcine adenoviruses, (Adenoviridae), Porcine astrovirus, (Astroviridae), Porcine circovirus, Circoviridae, Porcine enteric calicivirus, (Caliciviridae), Porcine enterovirus, (Picornaviridae), Porcine epidemic diarrhea virus, (Coronaviridae), Porcine hemagglutinating encephalomyelitis virus, (Coronaviridae), Porcine parvovirus, (Parvoviridae), Porcine respiratory and reproductive syndrome, (Arterivirus), Porcine rubulavirus, (Paramyxoviridae), Porcine transmissible gastroenteritis virus, (Coronaviridae), Porcine type C oncovirus, (Retroviridae), Porton virus, (Rhabdoviridae), Potosi virus, (Bunyaviridae), Powassan virus, (Flaviviridae), Precarious Point virus, (Bunyaviridae), Pretoria virus, (Bunyaviridae), Primate calicivirus, (Caliciviridae), Prospect Hill virus, (Bunyaviridae), Pseudaletia includens densovirus, (Parvoviridae), Pseudocowpox virus, (Poxyiridae), Pseudolumpy skin disease virus, (Herpesviridae), Pseudorabies virus, (Herpesviridae), Psittacid herpesvirus, (Herpesviridae), Psittacinepox virus, (Poxyiridae), Puchong virus, (Rhabdoviridae), Pueblo Viejo virus, (Bunyaviridae), Puffin island virus, (Bunyaviridae), Punta Salinas virus, (Bunyaviridae), Punta Toro virus, (Bunyaviridae), Purus virus, (Reoviridae), Puumala virus, (Bunyaviridae), Qalyub virus, (Bunyaviridae), Quailpox virus, (Poxyiridae), Quokkapox virus, (Poxyiridae), Rabbit coronavirus, (Coronaviridae), Rabbit fibroma virus, (Poxyiridae), Rabbit hemorrhagic disease virus, (Caliciviridae), Rabbit kidney vacuolating virus, (Papovaviridae), Rabbit oral papillomavirus, (Papovaviridae), Rabbitpox virus, (Poxyiridae), Rabies virus, (Rhabdoviridae), Raccoon parvovirus, (Parvoviridae), Raccoonpox virus, (Poxyiridae), Radi virus, (Rhabdoviridae), Rangifer tarandus herpesvirus, (Herpesviridae), Ranid herpesvirus, (Herpesviridae), Raphanus virus, (Rhabdoviridae), Rat coronavirus, (Coronaviridae), Rat cytomegalovirus, (Herpesviridae), Rat virus, R, (Parvoviridae), Raza virus, (Bunyaviridae), Razdan virus, (Bunyaviridae), Red deer herpesvirus, (Herpesviridae), Red kangaroopox virus, (Poxyiridae), Reed Ranch virus, (Rhabdoviridae), herpesvirus, (Herpesviridae), Reindeer papillomavirus, (Papovaviridae), Reptile calicivirus, (Caliciviridae), Resistencia virus, (Bunyaviridae), Restan virus, (Bunyaviridae), Reticuloendotheliosis virus, (Retroviridae), Rhesus HHV-like virus, (Herpesviridae), Rhesus leukocyte associated herpesvirus strain, (Herpesviridae), Rhesus monkey cytomegalovirus, (Herpesviridae), Rhesus monkey papillomavirus, (Papovaviridae), Rheumatoid arthritis virus, (Parvoviridae), Rift Valley fever virus, (Bunyaviridae), Rinderpest virus, (Paramyxoviridae), Rio Bravo virus, (Flaviviridae), Rio Grande virus, (Bunyaviridae), RML virus, (Bunyaviridae), Rochambeau virus, (Rhabdoviridae), Rocio virus, (Flaviviridae), Ross River virus, (Togaviridae), Rost Islands virus, (Reoviridae), Rous sarcoma virus, (Retroviridae), Royal farm virus, (Flaviuiridae), RT parvovirus, (Parvoviridae), Rubella virus, (Togaviridae), Russian spring summer encephalitis virus, (Flaviviridae), S-virus, (Reoviridae), SA virus, (Herpesviridae), Sabio virus, (Arenaviridae), Sabo virus, (Bunyaviridae), Saboya virus, (Flaviviridae), Sacbrood virus, (Picornaviridae), Sagiyama virus, (Togaviridae), Saimiriine herpesvirus, (Herpesviridae), SaintAbb's Head virus, (Reoviridae), Saint-Floris virus, (Bunyaviridae), Sakhalin virus, (Bunyaviridae), Sal Vieja virus, (Flaviviridae), Salanga virus, (Bunyaviridae), Salangapox virus, (Poxyiridae), Salehabad virus, (Bunyaviridae), Salmonid herpesvirus, (Herpesviridae), Salmonis virus, (Rhabdoviridae), Sambucus vein clearing virus, (Rhabdoviridae), SanAngelo virus, (Bunyaviridae), San Juan virus, (Bunyaviridae), San Miguel sealion virus, (Caliciviridae), San Perlita virus, (Flaviviridae), Sand rat nuclear inclusion agents, (Herpesviridae), Sandfly fever Naples virus, (Bunyaviridae), Sandfly fever Sicilian virus, (Bunyaviridae), Sandjimba virus, (Rhabdoviridae), Sango virus, (Bunyaviridae), Santa Rosa virus, (Bunyaviridae), Santarem virus, (Bunyaviridae), Sapphire II virus, (Bunyaviridae), Saraca virus, (Reoviridae), Sarracenia purpurea virus, (Rhabdoviridae), Sathuperi virus, (Bunyaviridae), Saumarez Reef virus, (Flaviviridae), Sawgrass virus, (Rhabdoviridae), Schistocerca gregaria entomopoxvirus, (Poxyiridae), Sciurid herpesvirus, (Herpesviridae), Sciurid herpesvirus, (Herpesviridae), Sealpox virus, (Poxyiridae), Seletar virus, (Reoviridae) Semliki Forest virus, (Togaviridae), Sena Madureira virus, (Rhabdoviridae), Sendai virus, (Paramyxoviridae), Seoul Virus, (Bunyaviridae), Sepik virus, (Flaviviridae), Serra do Navio virus, (Bunyaviridae), Shamonda virus, (Bunyaviridae), Shark River virus, (Bunyaviridae), Sheep associated malignant catarrhal fever of, (Herpesviridae), Sheep papillomavirus, (Papovaviridae), Sheep pulmonary adenomatosis associated herpesvirus, (Herpesviridae), Sheeppox virus, (Poxyiridae), Shiant Islands virus, (Reoviridae), Shokwe virus, (Bunyaviridae), Shope fibroma virus, (Poxyiridae), Shuni virus, (Bunyaviridae), Sibine fusca densovirus, (Parvoviridae), Sigma virus, (Rhabdoviridae), Sikte water-borne virus, (Tombusviridae), Silverwater virus, (Bunyaviridae), virus, (Bunyaviridae), Simian adenoviruses, (Adenoviridae), Simian agent virus, (Papovaviridae), Simian enterovirus, (Picornaviridae), Simian foamy virus, (Retroviridae), Simian hemorrhagic fever virus, (Arterivirus), Simian hepatitis A virus, (Picornaviridae), Simian immunodeficiency virus, (Retroviridae), Simian parainfluenza virus, (Paramyxoviridae), Simian rotavirus SA, (Reoviridae), Simian sarcoma virus, (Retroviridae), Simian T-lymphotropic virus, (Retroviridae), Simian type D virus, (Retroviridae), Simian vancella herpesvirus, (Herpesviridae), Simian virus, (Papovaviridae), Simulium vittatum densovirus, (Parvoviridae), Sindbis virus, (Togaviridae), Sixgun city virus, (Reoviridae), Skunkpox virus, (Poxyiridae), Smelt reovirus, (Reoviridae), Snakehead rhabdovirus, (Rhabdoviridae), Snowshoe hare virus, (Bunyaviridae), Snyder-Theilen feline sarcoma virus, (Retroviridae), Sofyn virus, (Flaviviridae), Sokoluk virus, (Flaviviridae), Soldado virus, (Bunyaviridae), Somerville virus, (Reoviridae), Sparrowpox virus, (Poxyiridae), Spectacled caimanpox virus, (Poxyiridae), SPH virus, (Arenaviridae), Sphenicid herpesvirus, (Herpesviridae), Spider monkey herpesvirus, (Herpesviridae), Spondweni virus, (Flaviviridae), Spring viremia of carp virus, (Rhabdoviridae), Squirrel fibroma virus, (Poxyiridae), Squirrel monkey herpesvirus, (Herpesviridae), Squirrel monkey retrovirus, (Retroviridae), SR-virus, (Bunyaviridae), Sripur virus, (Rhabdoviridae), StAbbs Head virus, (Bunyaviridae), St. Louis encephalitis virus, (Flaviviridae), Starlingpox virus, (Poxyiridae), Stratford virus, (Flaviviridae), Strigid herpesvirus, (Herpesviridae), Striped bass reovirus, (Reoviridae), Striped Jack nervous necrosis virus, (Nodaviridae), Stump-tailed macaque virus, (Papovaviridae), Suid herpesvirus, (Herpesviridae), Sunday Canyon virus, (Bunyaviridae), Sweetwater Branch virus, (Rhabdoviridae), Swine cytomegalovirus, (Herpesviridae), Swine infertility and respiratory syndrome virus, (Arterivirus), Swinepox virus, (Poxyiridae), Tacaiuma virus, (Bunyaviridae), Tacaribe virus, (Arenaviridae), Taggert virus, (Bunyaviridae), Tahyna virus, (Bunyaviridae), Tai virus, (Bunyaviridae), Taiassui virus, (Bunyaviridae), Tamana bat virus, (Flaviviridae), Tamdy virus, (Bunyaviridae), Tamiami virus, (Arenaviridae), Tanapox virus, (Poxyiridae), Tanga virus, (Bunyaviridae), Tanjong Rabok virus, (Bunyaviridae), Taro bacilliform virus, (Badnavirus), Tataguine virus, (Bunyaviridae), Taterapox virus, (Poxyiridae), Tehran virus, (Bunyaviridae), Telok Forest virus, (Bunyaviridae), Tembe virus, (Reoviridae), Tembusu virus, (Flaviviridae), Tench reovirus, (Reoviridae), Tensaw virus, (Bunyaviridae), Tephrosia symptomless virus, (Tombusviridae), Termeil virus, (Bunyaviridae), Tete virus, (Bunyaviridae), Thailand virus, (Bunyaviridae), Theiler's murine encephalomyelitis virus, (Picornaviridae), Thermoproteus virus, Lipothrixviridae, Thiafora virus, (Bunyaviridae), Thimiri virus, (Bunyaviridae), Thogoto virus, (Orthomyxoviridae), Thormodseyjarklettur virus, (Reoviridae), Thottapalayam virus, (Bunyaviridae), Tibrogargan virus, (Rhabdoviridae), Tick-borne encephalitis virus, (Flaviviridae), Tillamook virus, (Bunyaviridae), Tilligerry virus, (Reoviridae), Timbo virus, (Rhabdoviridae), Tilmboteua virus, (Bunyaviridae), Tilmaroo virus, (Bunyaviridae), Tindholmur virus, (Reoviridae), Tlacotalpan virus, (Bunyaviridae), Toscana virus, (Bunyaviridae), Tradescantia/Zebrina virus, Potyviridae, Trager duck spleen necrosis virus, (Retroviridae), Tree shrew adenovirus, (Adenoviridae), Tree shrew herpesvims, (Herpesviridae), Triatoma virus, (Picornaviridae), Tribec virus, (Reoviridae), Trivittatus virus, (Bunyaviridae), Trombetas virus, (Bunyaviridae), Trubanarnan virus, (Bunyaviridae), Tsuruse virus, (Bunyaviridae), Tucunduba virus, (Bunyaviridae), Tumor virus X, (Parvoviridae), Tupaia virus, (Rhabdoviridae), Tupaiid herpesvirus, (Herpesviridae), Turbot herpesvirus, (Herpesviridae), Turbot reovirus, (Reoviridae), Turkey adenoviruses, (Adenoviridae), Turkey coronavirus, (Coronaviridae), Turkey herpesvirus, (Herpesviridae), Turkey rhinotracheitis virus, (Paramyxoviridae), Turkeypox virus, (Poxyiridae), Turlock virus, (Bunyaviridae), Turuna virus, (Bunyaviridae), Tyuleniy virus, (Flaviviridae) Uasin Gishu disease virus, (Poxyiridae), Uganda S virus, (Flaviviridae), Ulcerative disease rhabdovirus, (Rhabdoviridae), Umatilla virus, (Reoviridae), Umbre virus, (Bunyaviridae), Una virus, (Togaviridae), Upolu virus, (Bunyaviridae), UR sarcoma virus, (Retroviridae), Urucuri virus, (Bunyaviridae), Usutu virus, (Flaviviridae), Uting a virus, (Bunyaviridae), Utive virus, (Bunyaviridae), Uukuniemi virus, (Bunyaviridae) Vaccinia subspecies, (Poxyiridae), Vaccinia virus, (Poxyiridae), Vaeroy virus, (Reoviridae), Varicella-zoster virus, (Herpesviridae), Variola virus, (Poxyiridae), Vellore virus, (Reoviridae), Venezuelan equine encephalitis virus, (Togaviridae), Vesicular exanthema of swine virus, (Caliciviridae), Vesicular stomatitis Alagoas virus, Rkabdoviridae, Vesicular stomatitis Indiana virus, (Rhabdoviridae), Vesicular stomatitis New Jersey virus, (Rhabdoviridae), Vilyuisk virus, (Picornaviridae), Vinces virus, (Bunyaviridae), Viper retrovirus, (Retroviridae), Viral hemorrhagic septicemia virus, (Rhabdoviridae), Virgin River virus, (Bunyaviridae), Virus III, (Herpesviridae), Visna/maedi virus, (Retroviridae), Volepoxvirus, (Poxyiridae), Wad Medani virus, (Reoviridae), Wallal virus, (Reoviridae), Walleye epidermal hyperplasia, (Herpesviridae), Wanowrie virus, (Bunyaviridae), Warrego virus, (Reoviridae), Weddel water-borne virus, Tombusviridae, Weldona virus, (Bunyaviridae), Wesselsbron virus, (Flaviviridae), West Nile virus, (Flaviviridae), Western equine encephalitis virus, (Togaviridae), Wexford virus, (Reoviridae), Whataroa virus, (Togaviridae), Wildbeest herpesvirus, (Herpesviridae), Witwatersrand virus, (Bunyaviridae), Wongal virus, (Bunyaviridae), Wongorr virus, (Reoviridae), Woodchuck hepatitis B virus, (Hepadnaviridae), Woodchuck herpesvirus marmota, (Herpesviridae), Woolly monkey sarcoma virus, (Retroviridae), Wound tumor virus, (Reoviridae), WVU virus, (Reoviridae), WW virus, (Reoviridae), Wyeomyia virus, (Bunyaviridae), Xiburema virus, (Rhabdoviridae), Xingu virus, (Bunyaviridae), Y sarcoma virus, (Retroviridae), Yaba monkey tumor virus, (Poxyiridae), Yaba-virus, (Bunyaviridae), Yaba-virus, (Bunyaviridae), Yacaaba virus, (Bunyaviridae), Yaounde virus, (Flaviviridae), Yaquina Head virus, (Reoviridae), Yata virus, (Rhabdoviridae), Yellow fever virus, (Flaviviridae), Yogue virus, (Bunyaviridae), Yokapox virus, (Poxyiridae), Yokase virus, (Flaviviridae), Yucca baciliform virus, Badnavirus, Yug Bogdanovac virus, (Rhabdoviridae), Zaliv Terpeniya virus, (Bunyaviridae), Zea mays virus, (Rhabdoviridae), Zegla virus, (Bunyaviridae), Zika virus, (Flaviviridae), Zirqa virus, (Bunyaviridae).

Essential Oils:

Essential oils are volatile and liquid aroma compounds from natural sources, usually plants. Essential oils are not oils in a strict sense. Essential oils are usually prepared by fragrance extraction techniques such as distillation (including steam distillation), cold pressing, or extraction (maceration). Typically, essential oils are highly complex mixtures of often hundreds of individual chemical components.

A Non Limiting List of Essential Oils which can be Used in the Present Invention is as Follows (List D):

Agar oil, Ajwain oil, Angelica root oil, Anise oil (used medicinally), Asafoetida (used medicinally), Balsam oil, Basil oil, Bay (used in aromatherapeutic for sprains, colds, flu, insomnia, rheumatism), Bergamot oil (used in aromatherapy), Black Pepper essential oil (used for treating muscle aches, pains and strains), Buchu oil (used medicinally), Birch (aromatheapeutic used for gout, Rheumatism, Eczema, Ulcers), Camphor (used for cold, cough, fever, rheumatism, arthritis), Cannabis flower essential oil, Caraway oil (used in mouthwashes and toothpastes), Cardamom seed oil (used in aromatherapy and other medicinal applications), Carrot seed oil (used in aromatherapy), Cedarwood oil, Chamomile oil, Calamus Root (used medicinally), Cinnamon oil (used for flavoring and medicinally), Cistus species, Citronella oil (used medicinally), Clary Sage, Clove leaf oil (used as a topical anesthetic to relieve dental pain), Coriander, Costmary oil, Costus Root (used medicinally), Cranberry seed oil (equally high in omega-3 omega-6 fatty acids), Cubeb (used medicinally), Cumin oil/Black seed oil (used in veterinary medicine), Cypress, Cypriol, Curry leaf (used medicinally), Davana oil, Dill oil, Elecampane (used medicinally), Eucalyptus oil (used in medicine), Fennel seed oil (used medicinally, particularly for treating colic in infants), Fenugreek oil (used medicinally), Fir, Frankincense oil (used for aromatherapy), Galangal (used medicinally), Galbanum, Geranium oil (used medicinally), Ginger oil (used medicinally), Goldenrod, Grapefruit oil (used in aromatherapy), Henna oil (used medicinally), Helichrysum, Horseradish oil, Hyssop, Idaho Tansy, Jasmine oil, Juniper berry oil (used medicinally), Lavender oil (used medicinally), Laurus nobilis, Ledum, Lemon oil (used medicinally), Lemongrass (used to help treating fevers and infections), Lime (used as antiseptic, antiviral, bactericidal, disinfectant), Litsea cubeba oil, Mandarin, Marjoram, Melaleuca See Tea tree oil, Melissa oil (used medicinally), Mentha arvensis oil/Mint oil (used in flavoring toothpastes, mouthwashes and pharmaceuticals, as well as in aromatherapy and other medicinal applications), Mountain Savory, Mugwort oil, Mustard oil, Myrrh oil (used medicinally), Myrtle, Neem Tree Oil, Neroli (produced from the blossom of the bitter orange tree), Nutmeg, Orange oil, Oregano oil (contains thymol and carvacrol used to treat digestive problems), Orris oil (used medicinally), Palo Santo, Parsley oil, Patchouli oil, Perilla essential oil, Peppermint oil (used in a wide variety of medicinal applications), Petitgrain,

Pine oil (used in aromatherapy), Ravensara, Red Cedar, Rose oil, Rosehip oil (used medicinally), Rosemary oil (used medicinally), Rosewood oil (used medicinally), Sage oil (used medicinally), Sandalwood oil, Sassafras oil (used medicinally), Savory oil, Schisandra oil (used medicinally), Spearmint oil, Spikenard (used medicinally), Spruce, Star anise oil (90% of the world's star anise crop is used in the manufacture of Tamiflu, a drug used to treat influenza, and is hoped to be useful for avian flu), Tangerine, Tarragon oil (used medicinally), Tea tree oil (used medicinally), Thyme oil (used medicinally), Tsuga, Turmeric (used medicinally), Valerian (used medicinally), Vetiver oil (khus oil), Western red cedar, Wintergreen, Yarrow oil (used medicinally), Ylang-ylang, Zedoary (used medicinally).

DETAILED DESCRIPTION OF THE INVENTION

Carvone forms two mirror image forms or enantiomers: R-(−)-carvone smells like spearmint. Its mirror image, S-(+)-carvone, smells like caraway. The fact that the two enantiomers are perceived as smelling differently is a proof that olfactory receptors must contain chiral groups, allowing them to respond more strongly to one enantiomer than to the other. Not all enantiomers have distinguishable odors. Squirrel monkeys have also been found to be able to discriminate between carvone enantiomers. The two forms are also referred to by older names, with dextro-, d- referring to R-carvone, and laevo-, l- referring to S-carvone. In chemistry, a racemic mixture, or racemate is one that has equal amounts of left- and right-handed enantiomers of a chiral molecule. The present invention relates to S-(+)-carvone (also called (+)-carvone in the present invention) and R-(−)-carvone (also called (−)-carvone in the present invention).

Geraniol has two different diastereomers (also called cis-trans isomers) in the nature: Cis-geraniol and Trans-geraniol. The same applies for Cis-nerolidol and trans-nerolidol for example. In diastereomers the bond structure is the same, but the geometrical positioning of atoms and functional groups in space differs leading to different biological properties. For compounds with more than two substituents E-Z notation is used instead of trans and cis, respectively. The present invention concerns Trans-geraniol.

The present invention relates to a composition comprising in combination R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called “(−) carvone”) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called “(+) carvone”) and (2E)-3,7-dimethylocta-2,6-dien-1-ol (also called trans-geraniol) and at least one more component chosen among essential oils components in a pharmaceutically effective concentration for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses, said diseases are selected from the group consisting in: (broncho)-pneumonia, 3 day fever exanthema, acute and chronic hepatitis, acute fever, acute gastroenteritis caused by strains such as Desert Shield Lordsdale Mexico Norwalk Hawaii Snow Mountain Southampton virus, acute gastroenteritis caused by strains such as Houston/86 Houston/90 London 29845 Manchester Parkville Sapporo virus, acute hepatitis, acute respiratory distress syndrome, AIDS, Argentine hemorrhagic fever, arthralgia, avian flu, Bolivian hemorrhagic fever, Brazilian hemorrhagic fever, chickenpox, chronic hepatitis, coma, common cold infection, common cold symptoms, congenital infection, conjunctivitis, contagious eethyma, contagious pustular dermatitis, cornea, Creutzfeldt-Jakob-Disease, cryptic enteric infection, cytomegaloviral mononucleosis, dengue hemorrhagic fever (DHF), dengue shock syndrome (DSS), diarrhea, eczema, eczema herpaticum, encephalitis, encephalopathy, enteritis, epidemic nephropathy, epidemic polyarthritis and exanthema, epidermodysplasia veruciformis, Epstein-Barr virus infection, exanthema, exanthema in children, Fatal familial insomnia, febrile encephalitis, febrile illness, fever, formerly Human echovirus 22 23, gastroenteritis, gastrointestinal infections intracytoplasmic inclusion bodies, genital tract infections, haemolytic crisis in people with sickle cell disease, headaches, hemorrhagic fever, hemorrhagic fever w renal syndrome, herpetic encephalitis, Hodgkin's disease, Human coxsackievirus, Human coxsackievirus B1-6, Human echovirus 1-7 9 11-21 24-27 29-33, Human enterovirus 69, Human enterovirus 71 (hand foot and mouth disease), Human hepatitis virus A (HHAV), Human poliovirus, Human rhinovirus 1 2 7 9 11 15 16 21 29 36 39 49 50 58 62 65 85 89 hyperacute respiratory disease, Human rhinovirus 3 14 72, hyperacute respiratory disease, immune deficiency syndrome, infantile diarrhea, Infection with any dengue serotype (1-4), infectious mononucleosis, joint pain, Kaposi's sarcoma, keratoconjunctivitis, Kuru, lesions of coutanous sites, leucopoenia, liver cirrhosis, lower respiratory tract infection, lymphadenopathy, maculopapular rash, malignant tissue, measles, meningitis, mononucleosis (kissing disease), mumps, muscle pains, myocarditis, nephropathy, nephropathy in transplant patients, numbness, opportunistic infection, oral infections, orchitis, pancreatitis, pandemics, papilloma, paralysis, persistent infection of the kidney, persistent infections, persistent lymphopathy, pharyngeal conjunctivitis, pneumonia, primary hepatocellular carcinoma, pulmonary syndrome, rabies, rash, recurrent epidemics of respiratory disease, respiratory disease, respiratory illness, Roseola infantum, sarcoma, sever chills arthralgia, severe acute respiratory syndrome, severe encephalitis, shingles, sixth disease, skin and mucous membrane lesions, slim disease, sore throat, subacute sclerosing panencephalitis, superinfection with Deltavirus, ulceration, upper respiratory tract illness, Venezuelan hemorrhagic fever, vesicular pharyngitis, vesicular stomatitis with exanthema, viral polyarthritis and rush, viral warts, watery diarrhea, weakness, zoonotic, zoster, metaplasia, dysplasia, anaplasia, desmoplasia, carcinoma in situ, flu (influenza), invasive carcinoma.

The composition of the present invention is used for blocking the above mentioned viruses entering the host cell(s). The composition of the present invention is also used as a prophylactic. The composition of the present invention can be used as virus inhibitor within and outside the animal or human body. The compositions of the present invention can also be used as a disinfectant.

The composition of the present invention can be administered, orally, topically, by inhalation, by suppository, intravenously, subcutaneously, or intramuscularly. It is also possible to spray a condom with the composition of the present invention said composition is intended to treat sexual transmitted diseases. The composition of the present invention can be manufactured in form of a solid (powder, tablets), or semi solid (creams, foams) or in form of a liquid or in form of a gas (aerosol).

Working Combinations:

The composition must comprise at least R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (this formula represents the component “(−) carvone”) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (this formula represents the component “(+) carvone”) and (2E)-3,7-dimethylocta-2,6-dien-1-ol (this formula represents the component “Trans geraniol”).

The single general technical inventive concept of the present invention leading to a synergetic effect is: the combination of R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone and (2E)-3,7-dimethylocta-2,6-dien-1-ol and at least one more component chosen among essential oils in a pharmaceutically effective concentration.

The chemical formula referring to “2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone” is to be understood in the whole present invention as being the racemate of carvone, i.e. 50% of enantiomer R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone and 50% of enantiomer S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone.

The composition preferably comprises at least 10% by weight of each component. However, an amount of 10% to 35% by weight for each component may be preferable.

Using amounts less than 10% by weight of each component might conduct to a less effective antiviral effect.

Because the chemical structure of each component is very similar, thousands of working combinations are possible. Following are some of the tested working combinations (see the below mentioned examples) representing the most preferred embodiments of the present invention.

The common denominator for each composition of the below examples is R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone and (2E)-3,7-dimethylocta-2,6-dien-1-ol.

The composition of the present invention comprises R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone and (2E)-3,7-dimethylocta-2,6-dien-1-ol in combination with at least one more component selected from a list A consisting in:

LIST a: The 128 Essential Oils Components of the Present Invention are Defined as Follows:

(−)-alpha-Pinene

(−)-beta-Pinene

(−)-Borneol

(−)-Bornyl acetate

(−)-Camphor

(−)-Carveol

(−)-Caryophyllene oxide

(−)-Citronellal

(−)-Citronellol

(−)-Dihydrocarvyl acetate

(−)-Fenchone

(−)-Isopinocampheol

(−)-Isopulegol

(−)-Linalool

(−)-Menthol

(−)-Menthone

(−)-Menthyl acetate

(−)-Myrtenol

(−)-Perillylalcohol

(−)-trans-Myrtanol

(−)-Verbenone

(+)-2-Carene

(+)-alpha-Pinene

(+)-Borneol

(+)-Camphor

(+)-Citronellol

(+)-Cuparene

(+)-Dihydrocarveol

(+)-Dihydrocarvone

(+)-Fenchone

(+)-Isomenthol

(+)-Isopinocampheol

(+)-Menthol

(+)-Neomenthol

(+/−)-alpha-Pinene

(+/−)-alpha-Pinene

(+/−)-beta-Citronellol

(+/−)-Camphor

(+/−)-Linalool

(+/−)-Menthol

(+/−)-Neomenthol

(1R)-Chrysanthemolactone

(1S,2S)-10-Pinanol

(cis+trans)-Nerolidol

1,4-Cineole

1,8-Cineole

2-Isopropyl-5-methylphenol

2-Norbornanone

3-Carene

3-Octanone

4-Menthan-3-one

Acetic acid butylester

Acetic acid cinnamylester

Acetic acid heptylester

Acetic acid isobutylester

Acetic acid methylester

alpha-(−)-Bisabolol

alpha-Caryophyllene

alpha-Cedrene

alpha-Humulene

alpha-Ionone

alpha-Terpinene

alpha-Terpineol

Azulene

Benzoic acid eugenylester

beta-Cedrene

beta-Naphthol

beta-Thujaplicin

Butyl acetate

Cajeputol

Camphene

Cedar camphor

Cedrol

Chamazulen

Cinnamyl acetate

cis-Jasmone

cis-Nerolidol

Citral

Citronellol

Cuminaldehyde

Cypress camphor

Dihydrocarveol

Dillapiole

DL-Citronellyl acetate

Estragole

Eucalyptol

Eugenol methylether

Eugenylbenzoate

exo-2-Camphanol

Farnesol

Furfuryl acetate

Furfuryl alcohol

gamma-Terpinene

Geranyl acetate

Heptyl acetate

Isobornyl acetate

Isobornyl isovalerate

Isobutyl acetate

Isocineole

Isoeugenol

Isoeugenylacetate

Isolongifolene

Isomenthone

Isothymol

Lemonol

Linalool

Linalool oxide

Linalyl acetate

Nerol

Nootkatone

p-Allylanisole

Piperitone

R-(−)-alpha-Phellandrene

R-(+)-Limonene

R-(+)-Pulegone

S-(−)-Limonene

Sabinene

Sabinyl acetate

Terpinolene

Terpinyl acetate

Tetrahydrolinalool

trans-Nerolidol

trans-Stilbene

(cis+Trans)-1,2(+)-limonene oxide

Eugenol

farnesol

Lavendulol

Linalooloxide

in a pharmaceutically effective concentration for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses, said diseases are selected from the group consisting in: (broncho)-pneumonia, 3 day fever exanthema, acute and chronic hepatitis, acute fever, acute gastroenteritis caused by strains such as Desert Shield Lordsdale Mexico Norwalk Hawaii Snow Mountain Southampton virus, acute gastroenteritis caused by strains such as Houston/86 Houston/90 London 29845 Manchester Parkville Sapporo virus, acute hepatitis, acute respiratory distress syndrome, AIDS, Argentine hemorrhagic fever, arthralgia, avian flu, Bolivian hemorrhagic fever, Brazilian hemorrhagic fever, chickenpox, chronic hepatitis, coma, common cold infection, common cold symptoms, congenital infection, conjunctivitis, contagious eethyma, contagious pustular dermatitis, cornea, Creutzfeldt-Jakob-Disease, cryptic enteric infection, cytomegaloviral mononucleosis, dengue hemorrhagic fever (DHF), dengue shock syndrome (DSS), diarrhea, eczema, eczema herpaticum, encephalitis, encephalopathy, enteritis, epidemic nephropathy, epidemic polyarthritis and exanthema, epidermodysplasia veruciformis, Epstein-Barr virus infection, exanthema, exanthema in children, Fatal familial insomnia, febrile encephalitis, febrile illness, fever, formerly Human echovirus 22 23, gastroenteritis, gastrointestinal infections intracytoplasmic inclusion bodies, genital tract infections, haemolytic crisis in people with sickle cell disease, headaches, hemorrhagic fever, hemorrhagic fever w renal syndrome, herpetic encephalitis, Hodgkin's disease, Human coxsackievirus, Human coxsackievirus B1-6, Human echovirus 1-7 9 11-21 24-27 29-33, Human enterovirus 69, Human enterovirus 71 (hand foot and mouth disease), Human hepatitis virus A (HHAV), Human poliovirus, Human rhinovirus 1 2 7 9 11 15 16 21 29 36 39 49 50 58 62 65 85 89 hyperacute respiratory disease, Human rhinovirus 3 14 72, hyperacute respiratory disease, immune deficiency syndrome, infantile diarrhea, Infection with any dengue serotype (1-4), infectious mononucleosis, joint pain, Kaposi's sarcoma, keratoconjunctivitis, Kuru, lesions of coutanous sites, leucopoenia, liver cirrhosis, lower respiratory tract infection, lymphadenopathy, maculopapular rash, malignant tissue, measles, meningitis, mononucleosis (kissing disease), mumps, muscle pains, myocarditis, nephropathy, nephropathy in transplant patients, numbness, opportunistic infection, oral infections, orchitis, pancreatitis, pandemics, papilloma, paralysis, persistent infection of the kidney, persistent infections, persistent lymphopathy, pharyngeal conjunctivitis, pneumonia, primary hepatocellular carcinoma, pulmonary syndrome, rabies, rash, recurrent epidemics of respiratory disease, respiratory disease, respiratory illness, Roseola infantum, sarcoma, sever chills arthralgia, severe acute respiratory syndrome, severe encephalitis, shingles, sixth disease, skin and mucous membrane lesions, slim disease, sore throat, subacute sclerosing panencephalitis, superinfection with Deltavirus, ulceration, upper respiratory tract illness, Venezuelan hemorrhagic fever, vesicular pharyngitis, vesicular stomatitis with exanthema, viral polyarthritis and rush, viral warts, watery diarrhea, weakness, zoonotic, zoster, metaplasia, dysplasia, anaplasia, desmoplasia, carcinoma in situ, flu (influenza), invasive carcinoma.

The chemical components listed in the previously mentioned list A are components which are all present in different essential oils. The first component of list A is “(−)-alpha-Pinene” and the 128th and last component of list A is “Linalooloxide”.

The following examples correspond to pharmaceutical compositions having an effective antiviral effect.

The compositions of the present invention may preferably contain 4, 5, 6, 7, 8, 9, 10 components or even more components (e.g. 11, 19, 35, 67 or 131 components or even more components). The word “component(s)” can also be replaced by the word “substance(s)” or “compound(s)”.

The Compositions of the Present Invention are Defined as being the Following Compositions:

Compositions of the present invention:

TABLE C EXAMPLE 1 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 2 Cistral 3,7-Dimethyl-2,6-octadienal Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 3 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Azulene bicyclo[5.3.0]decapentaene (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 4 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 5 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (−)-Borneol 1,7,7-Trimethyl-bicyclo[2.2.1]heptan-2-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 6 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Borneol 1,7,7-Trimethyl-bicyclo[2.2.1]heptan-2-ol Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 7 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Cistral 3,7-Dimethyl-2,6-octadienal (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 8 Farnesol (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 9 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Eucalyptol 4,7,7-trimethyl-8-oxabicyclo[2.2.2]octane (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 10 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 11 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (−)-Menthol 5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 12 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol 2-Methyl-I-butanol 2-methylbutan-1-ol Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 13 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol 4-Cymene 1-methyl-4-propan-2-ylbenzene (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 14 Farnesyl acetate 3,7,11-trimethyldodeca-2,6,10-trienyl acetate Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 15 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene (−)-Menthylacetate [(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl] acetate (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 16 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol lsomenthone 5-methyl-2-propan-2-ylcyclohexan-1-one (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 17 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane trans-Nerolidol (6E)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 18 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol R-(+)-Limonene (4R)-1-methyl-4-prop-1-en-2-ylcyclohexene Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 19 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 20 Guaiazulene 1,4-dimethyl-7-propan-2-ylazulene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone ′ EXAMPLE 21 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene 2-Methyl-I-butanol 2-methylbutan-1-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 22 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (−)-Menthylacetate [(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl] acetate (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 23 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane 1 ,4-cisneole 4-methyl-1-propan-2-yl-7-oxabicyclo[2.2.1]heptane (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 24 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (+)-DihydrocalVeol 2-methyl-2-prop-1-en-2-ylcyclohexan-1-ol Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 25 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol (−)-Isopulegol 5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 26 alpha-Ionone (E)-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 27 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene R-(+)-Pulegone 5-methyl-2-propan-2-ylidenecyclohexan-1-one (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 28 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-Nerolidol 3,7,11-trimethyldodeca-1,6,10-trien-3-ol (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 29 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane 4-(4-Methoxyphenyl)-2-butanone 4-(4-methoxyphenyl)butan-2-one (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 30 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol 2-Methyl-3-buten-2-ol 2-methylbut-3-en-2-ol Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 31 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol cis-Jasmone 3-methyl-2-[(Z)-pent-2-enyl]cyclopent-2-en-1-one (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 32 cis-Jasmone 3-methyl-2-[(Z)-pent-2-enyl]cyclopent-2-en-1-one Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 33 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene alpha-Terpinene 1-methyl-4-propan-2-ylcyclohexa-1,3-diene (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 34 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (−)-cistronellol (3S)-3,7-dimethyloct-6-en-1-ol (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 35 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol Cinnamyl lacetate [(E)-3-phenylprop-2-enyl]acetate Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 36 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol (−)-Linalool 3,7-dimethylocta-1,6-dien-3-ol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 37 alpha-(−)-Bisabolol (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 38 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene (−)-Isopinocampheol 2,7,7-trimethylbicyclo[3.1.1]heptan-3-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 39 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol Eucalyptol 4,7,7-trimethyl-8-oxabicyclo[2.2.2]octane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 40 Isoeugenol 2-methoxy-4-[(E)-prop-1-enyl]phenol Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 41 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene gamma-Nonalactone 5-pentyloxolan-2-one (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 42 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (+)-Neomenthol (1S,2S,5R)-5-methyl-2-propan-2-ylcyclohexan-1-ol (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 43 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol Cuminaldehyde 4-propan-2-ylbenzaldehyde Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 44 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol R-(+)-Limonene (4R)-1-methyl-4-prop-1-en-2-ylcyclohexene (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 45 lsoeugenylacetate [2-methoxy-4-[(E)-prop-1-enyl]phenyl]acetate Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 46 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Menthyl salicylate (5-methyl-2-propan-2-ylcyclohexyl)2-hydroxybenzoate (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 47 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol (+)-Borneol 1,7,7-trimethylbicyclo[2.2.1]heptan-6-ol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 48 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-cistronellol (3S)-3,7-dimethyloct-6-en-1-ol Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 49 (cis + trans)-1,2-(−)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 50 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene DL-cistronellyl acetate 3,7-dimethyloct-6-enyl acetate (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 51 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 52 Eugenol methylether 1,2-dimethoxy-4-prop-2-enylbenzene Linalooloxide 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol (cis + trans)-1,2-(+)-Limonene oxide 1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane (+/−)-Isomenthol (1R,2S,5S)-5-methyl-2-propan-2-ylcyclohexan-1-ol gamma-Nonalactone 5-pentyloxolan-2-one Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2-methoxy-4-prop-2-enylphenol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 53 trans-Nerolidol (6E)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2,7,7-trimethylbicyclo[3.1.1]heptan-3-ol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 54 (cis + trans)-Nerolidol 3,7,11-trimethyldodeca-1,6,10-trien-3-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2,7,7-trimethylbicyclo[3.1.1]heptan-3-ol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 55 Lavendulol (±)-2-Isopropenyl-5-methyl-4-hexen-1-ol (−)-Carvone R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone Trans-Geraniol (2E)-3,7-dimethylocta-2,6-dien-1-ol Eugenol 2,7,7-trimethylbicyclo[3.1.1]heptan-3-ol (+)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone EXAMPLE 56 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 128 components listed in list A EXAMPLE 57 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 64 first components listed in list A EXAMPLE 58 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 64 last components listed in list A (i.e. the 65th to the 128th components) EXAMPLE 59 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 32 first components listed in list A EXAMPLE 60 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 32 last components listed in list A (i.e. the 97th to the 128th components) EXAMPLE 61 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 16 first components listed in list A EXAMPLE 62 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 16 last components listed in list A (i.e. the 113th to the 128th components) EXAMPLE 63 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 8 first components listed in list A EXAMPLE 64 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 8 last components listed in list A (i.e. the 121th to the 128th components) EXAMPLE 65 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 4 first components listed in list A EXAMPLE 66 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 4 last components listed in list A (i.e. the 125th to the 128th components) EXAMPLE 67 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 2 first components listed in list A EXAMPLE 68 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 2 last components listed in list A (i.e. the 127th to the 128th components) EXAMPLE 69 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the first component listed in list A: (−)-alpha-Pinene EXAMPLE 70 (−)-Carvone (+)-Carvone Trans-Geraniol combined with the 128th component listed in list A: Linalooloxide

Each component of the above mentioned examples can have a weight percentage (wt %) comprised between 0.05 and 80, or preferably between 5 to 50 or between 10 to 50 or between 10 to 35, more preferably between 0.05 and 35, most preferably between 5 and 35.

Each component contained in a composition of the above mentioned examples may contain the same or different ranges (in wt %) chosen among the previously mentioned ranges (in wt %). One or more component(s) contained in a composition of the above mentioned examples may also have different ranges (in wt %) as those previously mentioned.

Any specific component of any above mentioned example of Table C can be combined with any other specific component of any other example mentioned above in Table C in order to form a new composition.

3,7-Dimethyl-1,6-octadien-3-yl acetate can be replaced by other catalysers (components) depending on the type of application.

Certain components of the composition of the present invention can be enantiomer positive and/or enantiomer negative. Certain components do not have enantiomers. Other components can have Cis-isomer and/or Trans-isomer.

In the unprobable case that one or more of the above mentioned example(s) would have been known from a prior art document, we reserve the right to disclaim such example from the present invention.

The composition of the present invention may comprise at least 2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone and (2E)-3,7-dimethylocta-2,6-dien-1-ol in combination with at least one more component in a pharmaceutically effective concentration for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses, RNA non-enveloped viruses said diseases are selected from the group consisting in: (broncho)-pneumonia, 3 day fever exanthema, acute and chronic hepatitis, acute fever, acute gastroenteritis caused by strains such as Desert Shield Lordsdale Mexico Norwalk Hawaii Snow Mountain Southampton virus, acute gastroenteritis caused by strains such as Houston/86 Houston/90 London 29845 Manchester Parkville Sapporo virus, acute hepatitis, acute respiratory distress syndrome, AIDS, Argentine hemorrhagic fever, arthralgia, avian flu, Bolivian hemorrhagic fever, Brazilian hemorrhagic fever, chickenpox, chronic hepatitis, coma, common cold infection, common cold symptoms, congenital infection, conjunctivitis, contagious eethyma, contagious pustular dermatitis, cornea, Creutzfeldt-Jakob-Disease, cryptic enteric infection, cytomegaloviral mononucleosis, dengue hemorrhagic fever (DHF), dengue shock syndrome (DSS), diarrhea, eczema, eczema herpaticum, encephalitis, encephalopathy, enteritis, epidemic nephropathy, epidemic polyarthritis and exanthema, epidermodysplasia veruciformis, Epstein-Barr virus infection, exanthema, exanthema in children, Fatal familial insomnia, febrile encephalitis, febrile illness, fever, formerly Human echovirus 22 23, gastroenteritis, gastrointestinal infections intracytoplasmic inclusion bodies, genital tract infections, haemolytic crisis in people with sickle cell disease, headaches, hemorrhagic fever, hemorrhagic fever w renal syndrome, herpetic encephalitis, Hodgkin's disease, Human coxsackievirus, Human coxsackievirus B1-6, Human echovirus 1-7 9 11-21 24-27 29-33, Human enterovirus 69, Human enterovirus 71 (hand foot and mouth disease), Human hepatitis virus A (HHAV), Human poliovirus, Human rhinovirus 1 2 7 9 11 15 16 21 29 36 39 49 50 58 62 65 85 89 hyperacute respiratory disease, Human rhinovirus 3 14 72, hyperacute respiratory disease, immune deficiency syndrome, infantile diarrhea, Infection with any dengue serotype (1-4), infectious mononucleosis, joint pain, Kaposi's sarcoma, keratoconjunctivitis, Kuru, lesions of coutanous sites, leucopoenia, liver cirrhosis, lower respiratory tract infection, lymphadenopathy, maculopapular rash, malignant tissue, measles, meningitis, mononucleosis (kissing disease), mumps, muscle pains, myocarditis, nephropathy, nephropathy in transplant patients, numbness, opportunistic infection, oral infections, orchitis, pancreatitis, pandemics, papilloma, paralysis, persistent infection of the kidney, persistent infections, persistent lymphopathy, pharyngeal conjunctivitis, pneumonia, primary hepatocellular carcinoma, pulmonary syndrome, rabies, rash, recurrent epidemics of respiratory disease, respiratory disease, respiratory illness, Roseola infantum, sarcoma, sever chills arthralgia, severe acute respiratory syndrome, severe encephalitis, shingles, sixth disease, skin and mucous membrane lesions, slim disease, sore throat, subacute sclerosing panencephalitis, superinfection with Deltavirus, ulceration, upper respiratory tract illness, Venezuelan hemorrhagic fever, vesicular pharyngitis, vesicular stomatitis with exanthema, viral polyarthritis and rush, viral warts, watery diarrhea, weakness, zoonotic, zoster, metaplasia, dysplasia, anaplasia, desmoplasia, carcinoma in situ, flu (influenza), invasive carcinoma.

The present invention can also consist in a composition comprising a compound having a chemical Structure of formula A and Anti-viral properties in Vivo. This compound can be used as a medicament.

Formula A: C16H22O4

In order to produce this compound the man skilled in the art has two options.

Option 1:

Synthesize the compound using above-mentioned blueprint from scratch according to standard known synthesizing procedures used in the medical, food flavoring and fragrance industry. E.g. International Foods and Fragrances (USA), Givaudan (Swiss).

Option 2:

Combine existing components available in industry and attain an as close as possible combination, using the above mentioned compound (formula A) as a blueprint.

The man skilled in the art has over 40,000 natural registered Monoterpenes and over 60,000 Sequeterpenes to his disposal and obviously there are thousands possible combinations leading to the required chemical structure presented above.

An alternative similar compound having a chemical structure of formula B can also lead to production of an Antiviral medicament.

Formula B: C16H22O4

Minor deviations to the above blue print are possible to have a lesser or similar anti-viral effect in Vivo.

In order to prove the efficacy of above-mentioned compounds, the inventor has combined certain more common components (see Components list of Table C).

First, it was confirmed that none of the single components taken alone of the list had any anti viral effect In Vivo.

Further, components were identified that were common in all the tested formulations: Carvone(+), Carvone(−) and Trans-Geraniol.

As the majority of the components have very similar chemical structures, it is no undue burden for a man skilled in the art having both the blue print (formula A and B) of the ideal anti viral and 100,000 registered components to his disposal to combine several alternative components to achieve a similar result.

The composition of the present invention comprises a pharmaceutical compound of formula A or B:

Or

An example of a composition of the present invention comprises the following component(s) in the following ranges (wt %):

TABLE 1 Components of a More Most preferred embodiment preferred preferred of the composition Range 1 Range 2 Range 3 (example 53) in wt. % in wt. % in wt. % trans-Nerolidol 0.05 to 80 10 to 50 10 to 35 (−)-Carvone 0.05 to 80 10 to 50 10 to 35 Trans-Geraniol 0.05 to 80 10 to 50 10 to 35 Eugenol 0.05 to 80 10 to 50 10 to 35 (+)-Carvone 0.05 to 80 10 to 50 10 to 35

All values (i.e. any limit value of a range) mentioned on a same line in the above table can be combined together in order to form a new range combination for the specific component comprised in the composition.

The aim of table 1 is to give examples of ranges and specific values found for a specific component by techniques well known by a person skilled in the art.

Advantage of the Present Invention

An advantage of the antiviral compositions according to the present invention consists in that the composition is a mixture of components and so no simultaneous resistance can be developed to them all by the viruses. Moreover, the non-specific activity of the composition according to the invention is different to that of conventional drugs, enabling them to effectively treat and prevent diseases and not to be affected by the possible emergence of virus mutation.

Another advantage of the compositions according to the invention is that the components are lipophilic, being therefore able to easily cross between body and cellular compartments and accumulate in lipid-rich tissues.

Being volatile, the components of the compositions according to the invention can be excreted via the lungs: an added advantage when treating and preventing respiratory infections or inflammations. The components of the composition can be diffused into the atmosphere and fall onto exposed surface, deactivating viruses before they reach a potential host.

In order to prove the efficacy of the composition of the present invention, in vivo studies have been conducted. Following are examples of at least one virus belonging to each of the 4 major viral families.

In Vivo Tests:

Individual case studies were performed by medical practitioners that confirmed the potent activity of the present invention against all existing 4 families of viruses, namely:

-   -   DNA enveloped viruses (e.g. Herpes virus, Molluscum contagiosum,         Varicella-zoster).         -   DNA non-enveloped viruses (e.g. Papillomavirus, Parvovirus,             Adenovirus).         -   RNA enveloped viruses (e.g. Hepatitis C, Porcine             reproductive and respiratory syndrome virus (PPRS virus),             Coronavirus).         -   RNA non-enveloped viruses (e.g. Rotavirus, Rhinovirus,             Coxsackievirus).

Studies conducted by veterinarians involving over 700 animals, several observational studies on humans and ongoing double-blinded placebo controlled phase III clinical trials confirmed the efficiency of the present invention and did not show any toxic side effect.

In the present invention the novel synergetic antiviral compositions of Table C are always instilled on or in animals or humans after the viruses infected the animal or human body.

Mode of Action

The composition of the present invention deactivates viruses when they are in the free state, i.e. when they are not associated with cells, by interfering with the surface tension of the lipid coating of the viruses capsules thereby preventing the entry of the viruses in the animal or human cells and therefore the multiplication of the viruses in the cells. This had been determined by in vitro technology. This is in direct contrast to existing antiviral products, which only exert an effect once the viruses are associated with host cells. The composition of the present invention can act as an anti-infectious agent, inactivating viral particles before they contact the host. There is only one common mode of action of the composition of the present invention involved in all diseases; therefore there should be no need to provide tests for all diseases or all viruses specifically mentioned in the present application.

In Vivo Results:

The following examples have been taken from cases study results to highlight the activity of the antiviral composition for which the specific composition of example 1 and example 53 (see Table C) have been used in order to conduct all the mentioned tests. In the present invention the novel synergetic composition is always instilled on or in animals or humans after the viruses infected the animal or human body in order to treat animal or human diseases. The man skilled in the art knows how to perform the tests.

Percentage Component(s) by weight Composition of Example 53 contains (see Table C): R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone 12.5% (−)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone 12.5% (+)-Carvone (2E)-3,7-dimethylocta-2,6-dien-l-ol   25% Trans-Geraniol 2-methoxy-4-prop-2-enylphenol   25% Eugenol (6E)-3,7,11-trimethyldodeca-1,6,10-trien-3-o1   25% Trans-Nerolidol Composition of Example 1 contains (see Table C): Eugenol methylether 12.5% Linalooloxide 12.5% (cis+trans)-1 ,2-(+)-Limonene oxide 12.5% (+/−)-lsomenthol 12.5% (−)-Carvone 12.5% Trans-Geraniol 12.5% Eugenol 12.5% (+)-Carvone 12.5%

Similar or identical results showing an antiviral effect would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

RNA Enveloped Virus—Hepatitis C Virus:

In most instances, there is a slow, progressive asymptomatic hepatitis with persistent viraemia lasting many years. Only 5% of those infected show symptoms. Chronic infection occurs in 80% of those infected, showing a variety of debilitating conditions including kidney disease and 20% develop cirrhosis and hepatocellular carcinoma. Infection is caused by direct contact with contaminated blood and mother to infant transfer in commonplace.

The drug of choice is with IFN-alpha, but many cases relapse when the drug is stopped and less than 15% are permanently cured after more than a year of treatment.

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

Methods:

Patients:

Adult patients who had not previously taken interferon and who had the following characteristics were eligible for the study: a positive test for anti-HCV antibody, an HCV RNA level greater than 2000 copies per milliliter on polymerase-chain-reaction analysis, a serum alanine amino-transferase concentration above the upper limit of normal on two occasions during the preceding six months, and findings consistent with a diagnosis of chronic hepatitis C on liver biopsy performed during the preceding year, as determined by a single, study-designated pathologist.

Assessment and Endpoints:

Because of the specific mode of action of the composition, which is genotype neutral, no Hepatitis C virus genotyping was performed. The primary efficacy end points were an early virologic response (significant lowering of HCV RNA on analysis).

Results:

Characteristics of the Patients:

Of the 11 patients enrolled, 6 met the criteria for entry. Base loads ranged from 22,000,000 to 11,600. Five (5) patients were enrolled for a one-time 1 to 4 week treatment. One patient was enrolled for a long-term treatment.

Efficacy: 1-4 Weeks

All 6 patients were administered 350 μg of the composition of the present invention three times daily.

TABLE 2 Virological and Biological Response at Week 4 according to Intention-to-Treat Analysis P Name Date Base L Date Base + 1 Log EVR Log 1 Sherif  5 Jan. 2007 22.000.000 7, 3 17 Jan. 2007 1.360.000 6, 1 94% 1, 2 3 Adel 26 Jan. 2007 290.000 5, 5 10 Feb. 2007 54.020 4, 7 81% 0, 7 7 Fawzy 17 Feb. 2007 1.118.572 6, 0 11 Mar. 2007 111.144 5, 0 90% 1, 0 8 Fathy 18 Feb. 2007 1.950.00 6, 3 13 Mar. 2007 165.055 5, 2 92% 1, 1 11 Magded 17 Jan. 2007 11.600 4, 1  4 Mar. 2007 1.864 3, 3 84% 0, 8 2 Fatma 17 Jan. 2007 825.000 5, 9 27 Jan. 2007 501.000 5, 7 39% 0, 2

Efficacy of treatment with the composition was associated with a significant drop in viral load comparable with traditional treatment with peginterferon alfa-2a.

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

Efficacy: Interrupted Trial:

One patient was treated over a period of 30 weeks, during which the treatment was interrupted and restarted three times within three different intervals. He was administered the same dose, 350 μg of the composition three times daily for intervals ranging from 1 to 4 weeks.

TABLE 3 Virological and Biological Response with variable interruptions Intention-to-Treat Analysis Test Date Viral Load LOG WKs LOG Start / Stop 1 Base  5 Jan. 2007 22.000.000 7, 3 2 PCR 01 17 Jan. 2007 1.360.000 6, 1 2 −1, 2 3 PCR 02 24 Jan. 2007 453.000 5, 7 1 −0, 5 Interruption of treatment 4 PCR 03  1 Feb. 2007 5.658.000 6, 8 1   1, 1 Restart of treatment 5 PCR 04 17 Feb. 2007 1.118.572 6, 0 2 −0, 7 6 PCR 05 12 Mar. 2007 165.055 5, 2 3 −0, 8 Interruption of treatment 7 PCR 06  1 Jul. 2007 4.498.635 6, 7 10   1, 4 Restart of treatment 8 PCR 07 28 Aug. 2007 1.150.008 6, 1 4 −0, 6

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

Conclusion:

Multiple interruptions of the treatment with the composition did not affect its positive virological response, confirming its mode of action.

DNA Non-Enveloped Virus—Papilloma Virus:

A papilloma is a benign epithelial growth commonly referred to as a wart or verruca and is caused by over 40 different strains of Human Papillomavirus (HPV). The appearance and seriousness of the infection varies from one anatomical region to another. Genital warts is now considered to be the most common sexually transmitted disease in the USA, with over 6 million new cases a year and with over 30 million carriers in the USA alone. There is a strong association with HPV infection and cancer of the reproductive tract.

Test Results

The efficacy of the composition of the present invention on the Papilloma virus was performed on a stressed businessman, aged 34, who regularly endured outbreaks of genital viral warts due to the papilloma virus. This tended to occur once every two weeks. The composition was administered orally under the medical supervision of a doctor, 300 mg thrice daily for three days at the onset of an outbreak and the symptoms subsided. After 3 weeks all warts had disappeared. The patient reported no side effects and remains asymptomatic after 18 months.

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

Ongoing Randomized Placebo-Controlled Clinical Trial

A ongoing randomized, double-blind, placebo controlled trial at an Mexican Hospital is being conducted to compare the effectiveness and the patient tolerance of the composition of the present invention topically applied spray with those of a placebo spray in the treatment of viral induced cervical lesions. The results of this initial part of the study will also help to determine changes the treatment protocols, changes in recruitment, enrollment, and follow-up for the rest of the study. All subjects had cervical lesions, as confirmed by colposcopy examination. In the initial group 28 subjects were screened; 24 were confirmed positive. Sixteen were eliminated; four had cervical atrophy and 12 were excluded from the efficacy analysis for protocol violations. There were 10 subjects in the intent-to-treat analysis, and a separate efficacy analysis was done on four subjects. In total each subject was treated eight times in a period of four days. There was no difference between the two groups at baseline with respect to any clinical or demographic factor. Neither group experienced adverse effects. More than 65% of the lesions in the group treated with the composition of the present invention started to disappear after 1 day and nearly all lesions disappeared after 7 days, as compared to no disappearance of lesions in the placebo group. All subjects treated with the composition of the present invention showed complete deactivation of the viral infection versus no de-activation in the placebo group during the follow-up period. The safety record of the drug was satisfactory; there was no difference between the composition of the present invention and the placebo in side effects or pain. Topically applied the composition of the present invention is effective in the treatment of viral induced cervical lesions.

DNA Enveloped Virus—Herpes Simplex Virus Types 1 & 2

Virus types 1 and 2 are generally responsible for upper body (oropharyngeal, dermal, ophthalmic) and genital infections respectively. Skin and mucous membranes are entry points in which the virus multiples and causes painful vesicles; infection is caused by direct contact with infected secretions. The viruses lie dormant in nerve tissue and reactivation may occur, triggered by a variety of events such as colds, menstruation, etc. The majority of the adult population is infected, with an estimated 1 million new cases of sexually transmitted disease every year in the USA alone.

Test Results

Herpes Simplex Virus Type 1—Case Example

Several subjects with irregular, recurrent herpes infections of the lips were treated with oral application of the composition at the onset of an outbreak. The characteristic vesicles disappeared quickly and all patients have remained asymptomatic with no further treatment required.

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

Herpes Simplex Virus Type 2—Case Example

The efficacy of the composition on the Herpes simplex 2 virus was performed on female subject who suffered recurrent instances of genital herpes at the beginning of every menstrual cycle for 10 years. Existing treatment consisted of Zovirax 7-10 days on a monthly basis, which had proved to be ineffective. The composition was administered orally under medical supervision, 300 mg thrice daily for three days, commencing 24 hours before the expected onset of the next outbreak. This outbreak was prevented. Although the composition of the present invention was not administered the following month, no symptoms appeared and the subject has remained herpes-free for over 18 months.

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

RNA Enveloped Virus—PRRS Virus (Porcine Reproductive and Respiratory Syndrome)

PRRS is a major cause of disease in pigs; it is present in virtually all pig herds with 100% of adults being sero-positive. The disease is characterized by abortion and stillbirths in adults and respiratory disease, diarrhoea and poor growth characteristics in piglets. There is no conventional cure and treatment consists of managing secondary bacterial infections with antibiotics.

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

Test Results

The efficacy of the composition was tested at a pig breeding centre. The infection of the piglets with PPRS was confirmed by standard tests and observation of symptoms. Two hundred piglets were orally administered the composition 500 mg twice daily for 4 consecutive days and the results compared to non-treated control groups. The results are shown in Table 4.

TABLE 4 The results of PPRS infected piglets treated with the compostion versus to control groups PPRS infected piglets Treated with the Control Group Composition(¹) Untreated Group Piglets Virus Death Group Piglets Virus Deaths 1 50 50 1 5 50 0 5 2 50 50 1 6 50 0 3 3(²) 50 50 0 7 50 0 4 4(²) 50 50 0 8 50 0 5 Total 200 200 2 200 0 17 1% 8.5% (¹)composition administered 1 to 2 days after birth (²)composition administered immediately at birth (³)After 4 days

Laboratory analysis demonstrated that the piglets in the test group were PPRS-free after 4 days whereas the control animals were still infected. The results showed that the death rate was reduced from 8.5% to 1% by the administration of the composition and it was noted that the treated piglets had improved appetite and growth rates as compared to the controls.

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

DNA Non-Enveloped Virus—Canine Parvovirus

Parvovirus is a highly contagious disease and major killer of puppies. It is characterized by bloody diarrhoea and progresses rapidly, with death occurring often within 2 days. It is transmitted via infected faeces. There is no conventional cure and treatment is limited to supportive therapy such as intravenous electrolytes. Infected adult dogs often show no symptoms and high levels of maternal parvovirus antibodies in the puppies' bloodstream interfere with vaccination, rendering it ineffective for the first 2-3 weeks.

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

Test Results

Recurrent Parvovirus outbreaks at a Belgian kennel had resulted in a death rate of over 90%. Puppies developed symptoms of the disease 10-14 days after birth and the presence of Parvovirus was determined by laboratory tests conducted by Klinische Laboratorium Herentals. The efficacy of the composition on this virus was supervised by two doctors who coordinated the treatment, which consisted of the oral administration of the composition, 500 mg twice daily for 7 days. A Veterinarian followed up the treatment. Due to the commercial nature of the kennels, a control group could not be instigated. 1 to 3 days after the beginning of treatment the symptoms had disappeared in the majority of puppies. After 7 days the puppies were tested and found to be virus-free. The results are shown in Table 5.

TABLE 5 The composition treatment of puppies infected with Parvovirus Very Bitch Puppies Sick Sick Dying Cured Death Beagle 1 6 2 2 1 5 1 Dalmatian 6 3 2 1 5 1 Golden Retriever 1 7 0 7 0 7 0 Border Collie 1 7 0 7 0 7 0 Berner Senner 3 3 0 0 3 0 Ruw H. Teckel 6 6 0 0 6 0 Malterzer 5 5 0 0 5 0 Golden Retriever 2 5 4 1 0 4 1 Golden Retriever 3 7 6 1 0 6 1 Labrador 2 8 8 0 0 8 0 Border Collie 2 7 6 1 0 6 1 Malterzer 2 3 3 0 0 3 0 Bobtail 2 2 0 0 2 0 Labrador 3 4 4 0 0 4 0 Beagle 2 7 0 7 0 7 0 Labrador 4 2 0 2 0 2 0 Siberian Huski 8 8 0 0 8 0 Golden Retriever 4 5 4 1 0 4 1 Golden Retriever 5 7 7 0 0 7 0 Golden Retriever 6 11 11 0 0 11 0 116 82 31 2 110 6 95% 5%

Treatment of the puppies with the composition reduced the death rate from over 90% to 5%.

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

DNA Enveloped Virus—Canine Herpes Virus

Canine Herpes Virus is a leading case of puppy deaths. It lives in the respiratory and reproductive tracts of adult dogs, which show no symptoms. It is transferred to puppies during birth and via airborne nasal secretions once born. It is very contagious and spreads rapidly through litters, causing liver damage, haemorrhages, blindness and staggering. Death occurs within 24-48 hours. There is no conventional cure and treatment aimed at supportive care. Vaccination does not exist.

Test Results

There was a high infection rate of canine Herpes virus in a breeding kennel, with over 40% of the puppies suffering from this deadly disease. In order to test the efficacy of the composition on its potential to eliminate future infections, the bitches were administered the composition before delivery of the puppies, since this disease is passed from symptom-free mother to their offspring. Approximately one week before giving birth, the mothers were orally administered the composition 500 mg twice daily for 7 days. See table 6.

TABLE 6 herpes infection rates in puppies from mothers pretreated with the composition Bitch Puppies Birth date Herpes free Chow-chow 4 Feb. 13 4 Border collie 8 Feb. 15 8 Chi-Tzu 4 Feb. 15 4 Jack-russel 4 Feb. 17 4 Golden retriever 6 Feb. 21 6 Snauzer 10 Feb. 21 10 Total 36 36 (100%)

Unlike conventional anti-virals, the composition is non toxic and an effective treatment can be achieved in days rather than in weeks or months.

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

RNA Non-Enveloped Virus—Rotavirus

The Rotaviruses are the most common cause of diarrhoea in young animals, causing a 20% death rate 7-10 days after birth. The disease is often complicated by a secondary infection with Escherichia coli. These viruses are also associated with a wide range of similar infections in humans, especially infants.

Test Results

A pig breeding centre in Belgium experienced an epidemic of rotavirus and over 500 piglets demonstrated severe diarrhoeal symptoms. It was expected that more than 25% would die within a week since there was no effective treatment. All of the animals were administered the composition and after 3 days, 95% of the piglets were devoid of symptoms and free of the virus.

Similar or identical results as with the composition of example 1 or example 53 (see Table C) would have been achieved by using any combination of components defined in claim 1 of the present invention and/or in examples 1 to 70 of the present invention (see Table C).

Tests Results Conclusions:

Independently of the fact that the treated viruses belonged to the RNA, DNA, enveloped or non-enveloped groups, the composition of the present invention interferes with the existing or acquired lipid envelope covering the virus and not with the virus per se; all studies indicate that the composition is capable of de-activating every type of virus in a free state.

Administration of the Composition:

The best mode administering the composition is one drop or +0.05 ml per 10 kg body weight (not including excess body fat), three times daily orally. The man skilled in the art can adapt the recommended dose per kg to the average weight of a human (50 kg). Preferably encapsulated but can be taken orally mixed with fruit juice or yoghurt, topically mixing with macadamia-type oil for fast skin absorption and petroleum jelly for slow topical absorption. For administering to animals composition can be mixed with the feed. Aerosol or topical application according to standard aerosol dispersions methods. Rectal or vaginal insertion of suppository with indicated dose according to standard suppository administration methods.

Process of Manufacture and Galenics:

All components are manufactured and available from a specialized open market. The purity of the components preferably has to be ≧99% and this is verified before the formulation process by gas chromatography/mass spectrometry.

Preferably the components have to be pre-blended, in equal or different parts, using a sterile blending device. The preferred temperature of manufacturing and storage of the composition is between 5 and 15 degrees Celcius.

After the pre-blending process the mixture can be added to a pharmaceutically acceptable carrier. Depending on the type of application, the ratio between the composition of the present invention and the pharmaceutically acceptable carrier can range from 5% to 90%, where 50% is the most common ratio used for practical medical applications.

The mixture can then be further processed and integrated in capsules, gels, gelules, sprays, aerosols, suppositories or other drug delivery vehicles.

The method for manufacturing the compositions of the present invention comprises the following steps:

-   -   pre-blending the components of the present invention at a         temperature comprised preferably between 5 and 15° C.,     -   obtention of a mixture,     -   addition of the mixture to a diluent (a pharmaceutically         acceptable carrier).

The presence of a pharmaceutically acceptable carrier is optional and depends on the type of drug delivery vehicle.

The person skilled in the art knows how to manufacture the compositions of the present invention (see the compositions of Table C).

Comparative Tests (In Vivo):

The hereunder mentioned comparative tests are aimed to establish observation(s) after 10 days on 44 female human patients by Controlled Clinical Trial on Cervical Lesions (wounds) caused by the Human Papilloma Virus (HPV) which is a double stranded DNA non enveloped virus. HPV is a virus of a similar type than Adenovirus type 6 (double stranded DNA non enveloped virus).

In order to establish the non-activity of possible placebo's to be used in the clinical trial, 44 HPV infected patients were treated with a one-time dose of Placebos compositions.

AV1-HPV refers to the composition of example 1 of the present patent application (see Table C) inoculated to human patients with HPV cervical lesions.

AV53-HPV refers to the composition of example 53 of the present patent application (see Table C) inoculated to human patients with HPV cervical lesions.

The results indicate that the treatment with the 7 Placebos had no effect on de-activation of the HPV and the subsequent regression of the lesions on the surface of the cervix (also called neck of the uterus).

The person skilled in the art knows how to perform such tests.

Results:

Percentage by Treatment Component(s) weight Observation(s) after 10 days Placebo 1 R-(−)-Carvone 100% No regression of lesions on the surface of the cervix Placebo 2 S-(+)-Carvone 100% No regression of lesions on the surface of the cervix Placebo 3 (R)-Carvone 50%-50% No regression of lesions on carvone + the surface of the cervix (racemate) (S)-Carvone Placebo 4 Trans-Geraniol 100% No regression of lesions on the surface of the cervix Placebo 5 (R) Carvone + 50%-50% No regression of lesions on Trans-Geraniol the surface of the cervix Placebo 6 (S) Carvone + 50%-50% No regression of lesions on Trans-Geraniol the surface of the cervix Placebo 7 Carvone (racemate) + 50%-50% No regression of lesions on Trans-Geraniol the surface of the cervix Placebo 8 Eugenol 100% No regression of lesions on the surface of the cervix Placebo 9 Trans Nerolidol 100% No regression of lesions on the surface of the cervix Placebo 10 Eugenol +Carvone 50%-50% No regression of lesions on (racemate) the surface of the cervix Placebo 11 Eugenol +Trans 50%-50% No regression of lesions on Geraniol the surface of the cervix Placebo 12 Eugenol +Trans 50%-50% No regression of lesions on Nerolidol the surface of the cervix Placebo 13 Eugenol + Carvone 33.33%-33.33%- No regression of lesions on (racemate) +trans 33.33% the surface of the cervix Nerolidol Placebo 15 Eugenol +Trans 33.33%-33.33%- No regression of lesions on Geraniol + Trans 33.33% the surface of the cervix Nerolidol Placebo 16 Eugenol methyl ether 100% No regression of lesions on the surface of the cervix Placebo 17 Linalooloxide 100% No regression of lesions on the surface of the cervix Placebo 18 (cis+trans)-1,2-(+)- 100% No regression of lesions on Limonene oxide the surface of the cervix Placebo 19 (+/−)-lsomenthol 100% No regression of lesions on the surface of the cervix Placebo 20 (cis/trans) Nerolidol 100% No regression of lesions on the surface of the cervix Placebo 21 Lavendulol 100% No regression of lesions on the surface of the cervix Placebo 22 Eugenol methyl ether +  20% No regression of lesions on Linalooloxide +  20% the surface of the cervix (cis+trans)-1,2-(+)-  20% Limonene oxide +  20% (+ /-)-Isomenthol +  20% Eugenol Placebo 23 (cis/trans) Nerolidol + 50% each No regression of lesions on Eugenol the surface of the cervix Placebo 24 Lavendulol + 50% each No regression of lesions on Eugenol the surface of the cervix AV1-HPV See the composition 100% in total Between 30-100% regression of Example 1 of lesions on the surface of the cervix (on the page following this table) AV53-HPV See the composition 100% in total Between 30-100% regression of Example 53 of lesions on the surface of the cervix (on the page following this table) AV56-HPV See the composition 100% in total Between 20-100% regression of Example 56 of lesions on the surface of the cervix (on the page following this table) AV57-HPV See the composition 100% in total Between 20-100% regression of Example 57 of lesions on the surface of the cervix (on the page following this table) AV58-HPV See the composition 100% in total Between 20-100% regression of Example 58 of lesions on the surface of the cervix (on the page following this table) AV59-HPV See the composition Between 20-100% regression of Example 59 100% in total of lesions on the surface of the cervix (on the page following this table) AV60-HPV See the composition 100% in total Between 20-100% regression of Example 60 of lesions on the surface of (on the page the cervix following this table) AV61-HPV See the composition 100% in total Between 20-100% regression of Example 61 of lesions on the surface of (on the page the cervix following this table) AV62-HPV See the composition 100% in total Between 20-100% regression of Example 62 of lesions on the surface of (on the page the cervix following this table) AV63-HPV See the composition 100% in total Between 20-100% regression of Example 63 of lesions on the surface of (on the page the cervix following this table) AV64-HPV See the composition 100% in total Between 20-100% regression of Example 64 of lesions on the surface of (on the page the cervix following this table) AV65-HPV See the composition 100% in total Between 20-100% regression of Example 65 of lesions on the surface of (on the page the cervix following this table) AV66-HPV See the composition 100% in total Between 20-100% regression of Example 66 of lesions on the surface of (on the page the cervix following this table) AV67-HPV See the composition 100% in total Between 20-100% regression of Example 67 of lesions on the surface of (on the page the cervix following this table) AV68-HPV See the composition 100% in total Between 20-100% regression of Example 68 of lesions on the surface of (on the page the cervix following this table) AV69-HPV See the composition 100% in total Between 20-100% regression (on the page of lesions on the surface of of Example 69 the cervix following this table) AV70-HPV See the composition 100% in total Between 20-100% regression of Example 70 of lesions on the surface of (on the page the cervix following this table)

Percentage Treatment Component(s) by weight AV53- Composition of Example 53 (see table C) contains: HPV R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone 12.5% (R)-Carvone S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone 12.5% (S)-Carvone (2E)-3,7-dimethylocta-2,6-dien-l-ol   25% Trans-Geraniol 2-methoxy-4-prop-2-enylphenol   25% Eugenol (6E)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol   25% Trans-Nerolidol AV1-HPV Composition of Example 1 (see table C) contains: Eugenol methylether 12.5% Linalooloxide 12.5% (cis+trans)-1,2-(+)-Limonene oxide 12.5% (+/−)-lsomenthol 12.5% (−)-Carvone 12.5% Trans-Geraniol 12.5% Eugenol 12.5% (+)-Carvone 12.5% AV56-HPV Composition of Example 56 (see table C) contains: (−)-Carvone   10% (+)-Carvone   10% Trans-Geraniol   10% combined with the 128 components listed in list A 0.54% for each component AV57-HPV Composition of Example 57 (see table C) contains: (−)-Carvone   10% (+)-Carvone   10% Trans-Geraniol   10% combined with the 64 first components listed in list A 1.29% for each component AV58-HPV Composition of Example 58 (see table C) contains: (−)-Carvone   10% (+)-Carvone   10% Trans-Geraniol   10% combined with the 64 last components listed in list A 1.29% for each (i.e. the 65th to the 128th components) component AV59-HPV Composition of Example 59 (see table C) contains: (−)-Carvone   10% (+)-Carvone   10% Trans-Geraniol   10% combined with the 32 first components listed in list A 2.18% for each component AV60-HPV Composition of Example 60 (see table C) contains: (−)-Carvone   10% (+)-Carvone   10% Trans-Geraniol   10% combined with the 32 last components listed in list A 2.18% for each (i.e. the 97th to the 128th components) component AV61-HPV Composition of Example 61 (see table C) contains: (-)-Carvone   10% (+)-Carvone   10% Trans-Geraniol   10% combined with the 16 first components listed in list A 4.37% for each component AV62-HPV Composition of Example 62 (see table C) contains: (−)-Carvone   10% (+)-Carvone   10% Trans-Geraniol   10% combined with the 16 last components listed in list A 4.37% for each (i.e. the 112th to the 128th components) component AV63-HPV Composition of Example 63 (see table C) contains: (−)-Carvone   10% (+)-Carvone   10% Trans-Geraniol   10% combined with the 8 first components listed in list A 8.75% for each component AV64-HPV Composition of Example 64 (see table C) contains: (−)-Carvone   10% (+)-Carvone   10% Trans-Geraniol   10% combined with the 8 last components listed in list A 8.75% for each (i.e. the 121th to the 128th components) component AV65-HPV Composition of Example 65 (see table C) contains: (−)-Carvone 14.28% (+)-Carvone 14.28% Trans-Geraniol 14.28% combined with the 4 first components listed in list A 14.28% for each component AV66-HPV Composition of Example 66 (see table C) contains: (−)-Carvone 14.28% (+)-Carvone 14.28% Trans-Geraniol 14.28% combined with the 4 last components listed in list A 14.28% for each (i.e. the 125th to the 128th components) component AV67-HPV Composition of Example 67 (see table C) contains: (−)-Carvone   20% (+)-Carvone   20% Trans-Geraniol   20% combined with the 2 first components listed in list A 20% for each component AV68-HPV Composition of Example 68 (see table C) contains: (−)-Carvone   20% (+)-Carvone   20% Trans-Geraniol   20% combined with the 2 last components listed in list A the 20% for each (i.e. 127th to the 128th components) component AV69-HPV Composition of Example 69 (see table C) contains: (−)-Carvone   25% (+)-Carvone   25% Trans-Geraniol   25% combined with the first component listed in list A: 25% for each (−)-alpha-Pinene component AV70-HPV Composition of Example 70 (see table C) contains: (−)-Carvone   25% (+)-Carvone   25% Trans-Geraniol   25% combined with the 128th component listed in list A: 25% for each Linalooloxide component

Important Note:

The percentage of regression of the lesions observed on the surface of the cervix (i.e. between 20-100%) applies to composition(s) containing:

(+)-Carvone+(−)-Carvone+Trans-Geraniol in combination with at least one more component selected from the list of claim 1 (essential oils components of list A).

The specific examples for proving that all components of claim 1 are comprised within the scope of the present invention are those mentioned in examples 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 and 70 (see Table C and the corresponding percentages by weight mentioned previously).

The results of example 1 and example 53 (i.e. between 30-100% regression of lesions on the surface of the cervix) are even better than those of examples 56 to 70 (corresponding to list A) (i.e. between 20-100% regression of lesions on the surface of the cervix). No regression of lesions on the surface of the cervix have been observed (for placebo's compositions 1 to 24).

Dilution:

The Placebo's and the composition(s) of the present invention can also be diluted in using Biological Virgin Oil (50% by weight of virgin olive oil) to enable more even application to the Cervix.

The results obtained for the diluted composition(s) of the present invention mentioned previously are:

-   -   between 30-100% regression of lesions on the surface of the         cervix for the diluted composition of example 1 or example 53.     -   between 20-100% regression of the lesions observed on the         surface of the cervix (for diluted composition of examples 56 to         70 (see list A).     -   no regression of lesions on the surface of the cervix (for         diluted placebo's compositions 1 to 24).

Conclusion:

A synergism therefore exists between (+)carvone and (−)carvone and trans-geraniol and additional essential oils component(s) of the present composition(s).

There is a surprising and unexpected effect (in terms of regression of lesions on the surface of the cervix) to use the pure or diluted composition(s) of the present invention compared to the pure or diluted placebo compositions 1 to 24.

Placebo Examples for Making the Comparative Tests: Table B:

Placebo's given in the following comparative tests contained either 1 component (3 times 33.33%=100% wt) or a combination of 3 different components each in an amount of 33.33% by weight, except for example 55 having 4 different components, each in an amount of 25% by weight.

TABLE B Placebo Examples Component % Component % Component % Placebo (+)-Camphor 33.33% (−)-Fenchone 33.33% (+)-Neomenthol 33.33% Example 1 Placebo 1,8-Cineole 33.33% (+)-Isopinocampheol 33.33% R-(+)-Pulegone 33.33% Example 2 Placebo Camphene 33.33% (+)-Fenchone 33.33% beta-Naphthol 33.33% Example 3 Placebo trans-Nerolidol 33.33% trans-Nerolidol 33.33% trans-Nerolidol 33.33% Example 4 Placebo beta-Thujaplicin 33.33% Linalool 33.33% (−)-Verbenone 33.33% Example 5 Placebo (−)-Carveol 33.33% Heptyl acetate 33.33% Nootkatone 33.33% Example 6 Placebo (+/−)-Camphor 33.33% Furfuryl acetate 33.33% (+/−)-Neomenthol 33.33% Example 8 Placebo Acetic acid 33.33% (+)-Cuparene 33.33% Linalool 33.33% Example 9 methylester Placebo Geraniol 33.33% (+)-Carvone 33.33% (−)-Carvone 33.33% Example 10 Placebo (+)-Borneol 33.33% (−)-Dihydrocarvyl 33.33% (+/−)-Menthol 33.33% Example 11 acetate Placebo Tetrahydrolinalool 33.33% Estragole 33.33% (+)-Fenchone 33.33% Example 12 Placebo p-Allylanisole 33.33% Cypress camphor 33.33% Linalyl acetate 33.33% Example 13 Placebo Azulene 33.33% Dihydrocarveol 33.33% 4-Menthan-3-one 33.33% Example 14 Placebo (−)-Verbenone 33.33% alpha-Humulene 33.33% 2-Norbornanone 33.33% Example 15 Placebo (−)-Camphor 33.33% Furfuryl alcohol 33.33% Nerol 33.33% Example 16 Placebo 3-Carene 33.33% Geranyl acetate 33.33% cis-Nerolidol 33.33% Example 17 Placebo alpha- 33.33% alpha-Ionone 33.33% 3-Octanone 33.33% Example 18 Caryophyllene Placebo 1,4-Cineole 33.33% Isomenthone 33.33% Piperitone 33.33% Example 19 Placebo Eugenol 33.33% Eugenol 33.33% Eugenol 33.33% Example 20 Placebo Benzoic acid 33.33% (+)-Dihydrocarveol 33.33% (−)-Menthol 33.33% Example 21 eugenylester Placebo Terpinyl acetate 33.33% (+)-2-Carene 33.33% farnesol 33.33% Example 22 Placebo (−)-Bornyl acetate 33.33% Estragole 33.33% (−)-Menthone 33.33% Example 23 Placebo (−)-Carvone 33.33% (−)-Carvone 33.33% (−)-Carvone 33.33% Example 24 Placebo Butyl acetate 33.33% Eucalyptol 33.33% (−)-Menthyl 33.33% Example 25 acetate Placebo Citral 33.33% 2-Isopropyl-5- 33.33% Sabinyl acetate 33.33% Example 26 methylphenol Placebo Cajeputol 33.33% Eugenylbenzoate 33.33% (−)-trans- 33.33% Example 27 Myrtanol Placebo Linalool oxide 33.33% Linalool oxide 33.33% Linalool oxide 33.33% Example 28 Placebo Lavendulol 33.33% Lavendulol 33.33% Lavendulol 33.33% Example 29 Placebo (−)-Borneol 33.33% Dillapiole 33.33% (+/−)-Menthol 33.33% Example 30 Placebo alpha-Cedrene 33.33% Isobutyl acetate 33.33% (1S,2S)-10- 33.33% Example 31 Pinanol Placebo Chamazulen 33.33% Isoeugenylacetate 33.33% (+/−)-alpha- 33.33% Example 32 Pinene Placebo Acetic acid 33.33% (+)-Citronellol 33.33% S-(−)-Limonene 33.33% Example 33, 33 butylester Placebo (+)-Carvone 33.33% (+)-Carvone 33.33% (+)-Carvone 33.33% Example 34 Placebo (cis + trans)- 33.33% (cis + trans)-Nerolidol 33.33% (cis + trans)- 33.33% Example 35 Nerolidol Nerolidol Placebo (−)-Caryophyllene 33.33% Isobornyl acetate 33.33% (−)- 33.33% Example 36 oxide Perillylalcohol Placebo Eugenol 33.33% Eugenol methylether 33.33% Eugenol 33.33% Example 37 methylether methylether Placebo Cedar camphor 33.33% Isobornyl isovalerate 33.33% R-(−)-alpha- 33.33% Example 38 Phellandrene Placebo Cedrol 33.33% Isoeugenol 33.33% (−)-alpha- 33.33% Example 39 Pinene Placebo beta-Cedrene 33.33% Isocineole 33.33% (+)-alpha- 33.33% Example 40 Pinene Placebo (+)-Isomenthol 33.33% (+)-Isomenthol 33.33% (+)-Isomenthol 33.33% Example 41 Placebo (−)-Citronellol 33.33% Isothymol 33.33% alpha- 33.33% Example 42 Terpinene Placebo Geraniol 33.33% Geraniol 33.33% Geraniol 33.33% Example 43 Placebo (−)-Citronellal 33.33% (−)-Isopulegol 33.33% trans-Stilbene 33.33% Example 44 Placebo (1R)- 33.33% Isolongifolene 33.33% (−)-beta-Pinene 33.33% Example 45 Chrysanthemolactone Placebo exo-2-Camphanol 33.33% Farnesol 33.33% (−)-Myrtenol 33.33% Example 46 Placebo Cinnamyl acetate 33.33% (−)-Isopinocampheol 33.33% Sabinene 33.33% Example 47 Placebo (+/−)-beta- 33.33% cis-Jasmone 33.33% gamma-Terpinene 33.33% Example 48 Citronellol Placebo Terpinolene 33.33% Lemonol 33.33% alpha-Terpineol 33.33% Example 49 Placebo Acetic acid 33.33% Citronellol 33.33% R-(+)- 33.33% Example 50 cinnamylester Limonene Placebo Acetic acid 33.33% Cuminaldehyde 33.33% (−)-Linalool 33.33% Example 51 isobutylester Placebo (cis + Trans)-1,2(+)- 33.33% (cis + Trans)-1,2(+)- 33.33% (cis + Trans)-1,2(+)- 33.33% Example 52 limonene oxide limonene oxide limonene oxide Placebo alpha-(−)-Bisabolol 33.33% (+)-Dihydrocarvone 33.33% (+)-Menthol 33.33% Example 53 Placebo Acetic acid 33.33% DL-Citronellyl 33.33% (+/−)-Linalool 33.33% Example 54 heptylester acetate Placebo example 55: Eugenol methylether (25% wt) + Linalooloxide (25% wt) + (cis + trans)-1,2(+)-limonene oxide (25% wt) + (+)-isomenthol (25% wt).

All following comparative tests have been performed by using essential oils components having the following percentages by weight:

Examples 1 to 52 of Table C contain 12.5% by weight of each component.

Examples 53 to 55 of Table C contain 20% by weight of each component.

The components of examples 56 to 70 of Table C contain the following percentages by weight:

Percentage Component(s) by weight Composition of Example 56 (see table C) contains: (−)-Carvone 10% (+)-Carvone 10% Trans-Geraniol 10% combined with the 128 components 0.54% for listed in list A each component Composition of Example 57 (see table C) contains: (−)-Carvone 10% (+)-Carvone 10% Trans-Geraniol 10% combined with the 64 first components 1.29% for listed in list A each component Composition of Example 58 (see table C) contains: (−)-Carvone 10% (+)-Carvone 10% Trans-Geraniol 10% combined with the 64 last components listed in list A 1.29% for (i.e. the 65th to the 128th components) each component Composition of Example 59 (see table C) contains: (−)-Carvone 10% (+)-Carvone 10% Trans-Geraniol 10% combined with the 32 first components listed in list A 2.18% for each component Composition of Example 60 (see table C) contains: (−)-Carvone 10% (+)-Carvone 10% Trans-Geraniol 10% combined with the 32 last components listed in list A 2.18% for (i.e. the 97th to the 128th components) each component Composition of Example 61 (see table C) contains: (−)-Carvone 10% (+)-Carvone 10% Trans-Geraniol 10% combined with the 16 first components listed in list A 4.37% for each component Composition of Example 62 (see table C) contains: (−)-Carvone 10% (+)-Carvone 10% Trans-Geraniol 10% combined with the 16 last components listed in list A 4.37% for (i.e. the 112th to the 128th components) each component Composition of Example 63 (see table C) contains: (−)-Carvone 10% (+)-Carvone 10% Trans-Geraniol 10% combined with the 8 first components listed in list A 8.75% for each component Composition of Example 64 (see table C) contains: (−)-Carvone 10% (+)-Carvone 10% Trans-Geraniol 10% combined with the 8 last components listed in list A 8.75% for (i.e. the 121th to the 128th components) each component Composition of Example 65 (see table C) contains: (−)-Carvone 14.28% (+)-Carvone 14.28% Trans-Geraniol 14.28% combined with the 4 first components listed in list A 14.28% for each component Composition of Example 66 (see table C) contains: (−)-Carvone 14.28% (+)-Carvone 14.28% Trans-Geraniol 14.28% combined with the 4 last components listed in list A 14.28% for (i.e. the 125th to the 128th components) each component Composition of Example 67 (see table C) contains: (−)-Carvone 20% (+)-Carvone 20% Trans-Geraniol 20% combined with the 2 first components listed in list A 20% for each component Composition of Example 68 (see table C) contains: (−)-Carvone 20% (+)-Carvone 20% Trans-Geraniol 20% combined with the 2 last components listed in list A 20% for each (i.e. the 127th to the 128th components) component Composition of Example 69 (see table C) contains: (−)-Carvone 25% (+)-Carvone 25% Trans-Geraniol 25% combined with the first component listed in list A: 25% for each (−)-alpha-Pinene component Composition of Example 70 (see table C) contains: (−)-Carvone 25% (+)-Carvone 25% Trans-Geraniol 25% combined with the 128th component listed in list A: 25% for each Linalooloxide component RNA Enveloped Virus—PRRS Virus (Porcine Reproductive and Respiratory Syndrome)

An in vivo comparative study was done at a pig breeding center. The infection of the piglets with PPRS was confirmed by standard tests and observation of symptoms. 55 piglets were orally administered with 70 alternative compositions (compositions of examples 1-70 of table C) 50 to 200 mg twice daily for 2 to 5 consecutive days and the results are compared to 55 other piglets who received the placebo compositions of table B, 200 mg for 5 days.

Veterinary diagnosis combined with Laboratory analysis demonstrated that the piglets in the test group were PPRS-free after 2 to 5 days, whereas the piglets that received the placebo did not show any signs of improvement after 5 days.

The man skilled in the art knows how to perform such tests.

PPRS infected piglets - RNA Enveloped Treated with the Compositions of Table C Placebo of Table B Composition Placebo Virus free of the present Virus of table after 5 invention Dosage free B Used Dosage days Composition  50 mg 2 days Placebo 200 mg None Example 1 Example 1 Composition 200 mg 4 days Placebo 200 mg None Example 2 Example 2 Composition 200 mg 4 days Placebo 200 mg None Example 3 Example 3 Composition 200 mg 4 days Placebo 200 mg None Example 4 Example 4 Composition 200 mg 5 days Placebo 200 mg None Example 5 Example 5 Composition 200 mg 5 days Placebo 200 mg None Example 6 Example 6 Composition 200 mg 4 days Example 7 Composition 200 mg 4 days Placebo 200 mg None Example 8 Example 8 Composition 200 mg 4 days Placebo 200 mg None Example 9 Example 9 Composition 200 mg 5 days Placebo 200 mg None Example 10 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 11 Example 11 Composition 200 mg 4 days Placebo 200 mg None Example 12 Example 12 Composition 200 mg 4 days Placebo 200 mg None Example 13 Example 13 Composition 200 mg 5 days Placebo 200 mg None Example 14 Example 14 Composition 200 mg 5 days Placebo 200 mg None Example 15 Example 15 Composition 200 mg 5 days Placebo 200 mg None Example 16 Example 16 Composition 200 mg 4 days Placebo 200 mg None Example 17 Example 17 Composition 200 mg 5 days Placebo 200 mg None Example 18 Example 18 Composition 200 mg 4 days Placebo 200 mg None Example 19 Example 19 Composition 200 mg 4 days Placebo 200 mg None Example 20 Example 20 Composition 200 mg 4 days Placebo 200 mg None Example 21 Example 21 Composition 200 mg 4 days Placebo 200 mg None Example 22 Example 22 Composition 200 mg 4 days Placebo 200 mg None Example 23 Example 23 Composition 200 mg 4 days Placebo 200 mg None Example 24 Example 24 Composition 200 mg 4 days Placebo 200 mg None Example 25 Example 25 Composition 200 mg 4 days Placebo 200 mg None Example 26 Example 26 Composition 200 mg 4 days Placebo 200 mg None Example 27 Example 27 Composition 200 mg 4 days Placebo 200 mg None Example 28 Example 28 Composition 200 mg 4 days Placebo 200 mg None Example 29 Example 29 Composition 200 mg 4 days Placebo 200 mg None Example 30 Example 30 Composition 200 mg 4 days Placebo 200 mg None Example 31 Example 31 Composition 200 mg 4 days Placebo 200 mg None Example 32 Example 32 Composition 200 mg 4 days Placebo 200 mg None Example 33 Example 33 Composition 200 mg 4 days Placebo 200 mg None Example 34 Example 34 Composition 200 mg 5 days Placebo 200 mg None Example 35 Example 35 Composition 200 mg 5 days Placebo 200 mg None Example 36 Example 36 Composition 200 mg 4 days Placebo 200 mg None Example 37 Example 37 Composition 200 mg 4 days Placebo 200 mg None Example 38 Example 38 Composition 200 mg 4 days Placebo 200 mg None Example 39 Example 39 Composition 200 mg 4 days Placebo 200 mg None Example 40 Example 40 Composition 200 mg 4 days Placebo 200 mg None Example 41 Example 41 Composition 200 mg 4 days Placebo 200 mg None Example 42 Example 42 Composition 200 mg 4 days Placebo 200 mg None Example 43 Example 43 Composition 200 mg 4 days Placebo 200 mg None Example 44 Example 44 Composition 200 mg 4 days Placebo 200 mg None Example 45 Example 45 Composition 200 mg 4 days Placebo 200 mg None Example 46 Example 46 Composition 200 mg 4 days Placebo 200 mg None Example 47 Example 47 Composition 200 mg 4 days Placebo 200 mg None Example 48 Example 48 Composition 200 mg 4 days Placebo 200 mg None Example 49 Example 49 Composition 200 mg 4 days Placebo 200 mg None Example 50 Example 50 Composition 200 mg 4 days Placebo 200 mg None Example 51 Example 51 Composition 200 mg 5 days Placebo 200 mg None Example 52 Example 52 Composition 200 mg 3 days Placebo 200 mg None Example 53 Example 53 Composition  50 mg 2 days Placebo 200 mg None Example 54 Example 54 Composition 200 mg 4 days Placebo 200 mg None Example 55 Example 55 Composition 200 mg 4 days Placebo 200 mg None Example 56 Example 10 Composition 200 mg 4 days Placebo 200mg None Example 57 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 58 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 59 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 60 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 61 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 62 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 63 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 64 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 65 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 66 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 67 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 68 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 69 Example 10 Composition 200 mg 4 days Placebo 200 mg None Example 70 Example 10 RNA Non-Enveloped Virus—Rotavirus

An in vivo comparative test was done in a Pig breeding center on 55 Piglets infected with ROTAVIRUS. All piglets experienced severe diarrhea.

55 Piglets received each individually an alternative composition of between 50 mg and 200 mg of the list of alternative compositions Examples 1 to 70 (see the composition listed in Table C). After 2 to 3 days none of the Piglets experienced any diarrhea.

The 55 other piglets of the Placebo group were given 200 mg each individually composition of Placebo Components listed in table B. After 3 days all the Piglets of the placebo group still experienced diarrhea.

The man skilled in the art knows how to perform such tests.

Rota Virus - RNA Non Enveloped Treated with the Compositions of Table C Placebo of Table B Composition Virus of the present Virus free Placebo free after invention Dosage table B of Used Dosage 3 days Composition  50 mg 2 days Placebo 200 mg None Example 1 Example 1 Composition 200 mg 3 days Placebo 200 mg None Example 2 Example 2 Composition 200 mg 3 days Placebo 200 mg None Example 3 Example 3 Composition 200 mg 3 days Placebo 200 mg None Example 4 Example 4 Composition 200 mg 3 days Placebo 200 mg None Example 5 Example 5 Composition 200 mg 3 days Placebo 200 mg None Example 6 Example 6 Composition 200 mg 3 days Example 7 Composition 200 mg 3 days Placebo 200 mg None Example 8 Example 8 Composition 200 mg 3 days Placebo 200 mg None Example 9 Example 9 Composition 200 mg 3 days Placebo 200 mg None Example 10 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 11 Example 11 Composition 200 mg 3 days Placebo 200 mg None Example 12 Example 12 Composition 200 mg 3 days Placebo 200 mg None Example 13 Example 13 Composition 200 mg 3 days Placebo 200 mg None Example 14 Example 14 Composition 200 mg 3 days Placebo 200 mg None Example 15 Example 15 Composition 200 mg 3 days Placebo 200 mg None Example 16 Example 16 Composition 200 mg 3 days Placebo 200 mg None Example 17 Example 17 Composition 200 mg 3 days Placebo 200 mg None Example 18 Example 18 Composition 200 mg 3 days Placebo 200 mg None Example 19 Example 19 Composition 200 mg 3 days Placebo 200 mg None Example 20 Example 20 Composition 200 mg 3 days Placebo 200 mg None Example 21 Example 21 Composition 200 mg 3 days Placebo 200 mg None Example 22 Example 22 Composition 200 mg 3 days Placebo 200 mg None Example 23 Example 23 Composition 200 mg 3 days Placebo 200 mg None Example 24 Example 23 Composition 200 mg 3 days Placebo 200 mg None Example 25 Example 25 Composition 200 mg 3 days Placebo 200 mg None Example 26 Example 26 Composition 200 mg 3 days Placebo 200 mg None Example 27 Example 27 Composition 200 mg 3 days Placebo 200 mg None Example 28 Example 28 Composition 200 mg 3 days Placebo 200 mg None Example 29 Example 29 Composition 200 mg 3 days Placebo 200 mg None Example 30 Example 30 Composition 200 mg 3 days Placebo 200 mg None Example 31 Example 31 Composition 200 mg 3 days Placebo 200 mg None Example 32 Example 32 Composition 200 mg 3 days Placebo 200 mg None Example 33 Example 33 Composition 200 mg 3 days Placebo 200 mg None Example 34 Example 34 Composition 200 mg 3 days Placebo 200 mg None Example 35 Example 35 Composition 200 mg 3 days Placebo 200 mg None Example 36 Example 36 Composition 200 mg 3 days Placebo 200 mg None Example 37 Example 37 Composition 200 mg 3 days Placebo 200 mg None Example 38 Example 38 Composition 200 mg 3 days Placebo 200 mg None Example 39 Example 39 Composition 200 mg 3 days Placebo 200 mg None Example 40 Example 40 Composition 200 mg 3 days Placebo 200 mg None Example 41 Example 41 Composition 200 mg 3 days Placebo 200 mg None Example 42 Example 42 Composition 200 mg 3 days Placebo 200 mg None Example 43 Example 43 Composition 200 mg 3 days Placebo 200 mg None Example 44 Example 44 Composition 200 mg 3 days Placebo 200 mg None Example 45 Example 45 Composition 200 mg 3 days Placebo 200 mg None Example 46 Example 46 Composition 200 mg 3 days Placebo 200 mg None Example 47 Example 47 Composition 200 mg 3 days Placebo 200 mg None Example 48 Example 48 Composition 200 mg 3 days Placebo 200 mg None Example 49 Example 49 Composition 200 mg 3 days Placebo 200 mg None Example 50 Example 50 Composition 200 mg 3 days Placebo 200 mg None Example 51 Example 51 Composition 200 mg 3 days Placebo 200 mg None Example 52 Example 52 Composition 200 mg 3 days Placebo 200 mg None Example 53 Example 53 Composition  50 mg 2 days Placebo 200 mg None Example 54 Example 54 Composition 200 mg 3 days Placebo 200 mg None Example 55 Example 55 Composition 200 mg 3 days Placebo 200 mg None Example 56 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 57 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 58 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 59 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 60 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 61 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 62 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 63 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 64 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 65 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 66 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 67 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 68 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 69 Example 10 Composition 200 mg 3 days Placebo 200 mg None Example 70 Example 10 DNA Enveloped Virus—Herpes Simplex Virus

An in vivo comparative test was done on human subjects experiencing recurring Cold sores on the lips caused by the Herpes 1 Simplex Virus.

55 human subjects were treated with a separate alternative composition from the Composition of examples 1 to 70 of the present invention (see table C). Two drops containing 2 mg of the composition was administered topically on the lips between 1 to 5 times. Within one day the Cold sore stopped developing into a lesion.

The placebo group of other human subjects was treated with 5 times two drops containing 2 mg of the Placebo compositions (see Table B). After one day the Cold sores continued to develop into lesions.

The man skilled in the art knows how to perform such tests.

Herpes Labialis - DNA - Enveloped Treated with the Compositions of Table C Placebo of Table B Composition Lesion of the present App- Lesion Placebo App- stopped after invention lications stopped Used lications one day Composition 1 same day Placebo 5 none Example 1 Example 1 Composition 5 next day Placebo 5 none Example 2 Example 2 Composition 5 next day Placebo 5 none Example 3 Example 3 Composition 5 next day Placebo 5 none Example 4 Example 4 Composition 5 next day Placebo 5 none Example 5 Example 5 Composition 5 next day Placebo 5 none Example 6 Example 6 Composition 5 next day Placebo 5 none Example 7 Example 7 Composition 5 next day Placebo 5 none Example 8 Example 8 Composition 5 next day Placebo 5 none Example 9 Example 9 Composition 5 next day Placebo 5 none Example 10 Example 10 Composition 5 next day Placebo 5 none Example 11 Example 11 Composition 5 next day Placebo 5 none Example 12 Example 12 Composition 5 next day Placebo 5 none Example 13 Example 13 Composition 5 next day Placebo 5 none Example 14 Example 14 Composition 5 next day Placebo 5 none Example 15 Example 15 Composition 5 next day Placebo 5 none Example 16 Example 16 Composition 5 next day Placebo 5 none Example 17 Example 17 Composition 5 next day Placebo 5 none Example 18 Example 18 Composition 5 next day Placebo 5 none Example 19 Example 19 Composition 5 next day Placebo 5 none Example 20 Example 20 Composition 5 next day Placebo 5 none Example 21 Example 21 Composition 5 next day Placebo 5 none Example 22 Example 22 Composition 5 next day Placebo 5 none Example 23 Example 23 Composition 5 next day Placebo 5 none Example 24 Example 24 Composition 5 next day Placebo 5 none Example 25 Example 25 Composition 5 next day Placebo 5 none Example 26 Example 26 Composition 5 next day Placebo 5 none Example 27 Example 27 Composition 5 next day Placebo 5 none Example 28 Example 28 Composition 5 next day Placebo 5 none Example 29 Example 29 Composition 5 next day Placebo 5 none Example 30 Example 30 Composition 5 next day Placebo 5 none Example 31 Example 31 Composition 5 next day Placebo 5 none Example 32 Example 32 Composition 5 next day Placebo 5 none Example 33 Example 33 Composition 5 next day Placebo 5 none Example 34 Example 34 Composition 5 next day Placebo 5 none Example 35 Example 35 Composition 5 next day Placebo 5 none Example 36 Example 36 Composition 5 next day Placebo 5 none Example 37 Example 37 Composition 5 next day Placebo 5 none Example 38 Example 38 Composition 5 next day Placebo 5 none Example 39 Example 39 Composition 5 next day Placebo 5 none Example 40 Example 40 Composition 5 next day Placebo 5 none Example 41 Example 41 Composition 5 next day Placebo 5 none Example 42 Example 42 Composition 5 next day Placebo 5 none Example 43 Example 43 Composition 5 next day Placebo 5 none Example 44 Example 44 Composition 5 next day Placebo 5 none Example 45 Example 45 Composition 5 next day Placebo 5 none Example 46 Example 46 Composition 5 next day Placebo 5 none Example 47 Example 47 Composition 5 next day Placebo 5 none Example 48 Example 48 Composition 5 next day Placebo 5 none Example 49 Example 49 Composition 5 next day Placebo 5 none Example 50 Example 50 Composition 5 next day Placebo 5 none Example 51 Example 51 Composition 5 next day Placebo 5 none Example 52 Example 52 Composition 5 next day Placebo 5 none Example 53 Example 53 Composition 5 next day Placebo 5 none Example 54 Example 54 Composition 5 same day Placebo 5 none Example 55 Example 55 Composition 5 same day Placebo 5 none Example 56 Example 56 Composition 5 next day Placebo 5 none Example 57 Example 57 Composition 5 next day Placebo 5 none Example 58 Example 58 Composition 5 next day Placebo 5 none Example 59 Example 59 Composition 5 next day Placebo 5 none Example 60 Example 60 Composition 5 next day Placebo 5 none Example 61 Example 61 Composition 5 next day Placebo 5 none Example 62 Example 62 Composition 5 next day Placebo 5 none Example 63 Example 63 Composition 5 next day Placebo 5 none Example 64 Example 64 Composition 5 next day Placebo 5 none Example 65 Example 65 Composition 5 next day Placebo 5 none Example 66 Example 66 Composition 5 next day Placebo 5 none Example 67 Example 67 Composition 5 next day Placebo 5 none Example 68 Example 68 Composition 5 next day Placebo 5 none Example 69 Example 69 Composition 5 next day Placebo 5 none Example 70 Example 70 DNA Non-Enveloped Virus—Papilloma Virus:

An in vivo comparative test on Skin Warts caused by the Human Papilloma Virus was performed on human subjects who had at least one or more skin warts on the hands, arms or other parts of the body.

55 human subjects were treated a separate alternative composition from the composition Examples list of table C (compositions Examples 1-70). One drop containing (2 mg) of the composition was administered topically on the wart between 3 times for one day up to five times a day for 14 days (i.e. 70 applications). Viral deactivation was confirmed as soon as the wart started to feel soft. This occurred generally between 6 to 21 days. The wart started to disappear and generally was invisible within 30 to 45 days form the start of the study.

The placebo group of other human subjects applied one drop containing 2 mg of the placebo 5 times a day for 14 days (70 applications) see the compositions of table B. None of the Placebo subjects experience any softening of the warts and none of the warts disappeared even partly within 45 days.

The man skilled in the art knows how to perform such tests.

Papilloma warts - DNA Non Enveloped Treated with the Compositions of Table C Placebo of Table B Composition Placebo App- Wart free of the present App- Wart of table lica- after 45 invention lications free B Used tions days Composition  9 30 days Placebo 70 None Example 1 Example 1 Composition 70 45 days Placebo 70 None Example 2 Example 2 Composition 70 45 days Placebo 70 None Example 3 Example 3 Composition 70 45 days Placebo 70 None Example 4 Example 4 Composition 70 45 days Placebo 70 None Example 5 Example 5 Composition 70 45 days Placebo 70 None Example 6 Example 6 Composition 70 45 days Example 7 Composition 70 45 days Placebo 70 None Example 8 Example 8 Composition 70 45 days Placebo 70 None Example 9 Example 9 Composition 70 45 days Placebo 70 None Example 10 Example 10 Composition 70 45 days Placebo 70 None Example 11 Example 11 Composition 70 45 days Placebo 70 None Example 12 Example 12 Composition 70 45 days Placebo 70 None Example 13 Example 13 Composition 70 45 days Placebo 70 None Example 14 Example 14 Composition 70 45 days Placebo 70 None Example 15 Example 15 Composition 70 45 days Placebo 70 None Example 16 Example 16 Composition 70 45 days Placebo 70 None Example 17 Example 17 Composition 70 45 days Placebo 70 None Example 18 Example 18 Composition 70 45 days Placebo 70 None Example 19 Example 19 Composition 70 45 days Placebo 70 None Example 20 Example 20 Composition 70 45 days Placebo 70 None Example 21 Example 21 Composition 70 45 days Placebo 70 None Example 22 Example 22 Composition 70 45 days Placebo 70 None Example 23 Example 23 Composition 70 45 days Placebo 70 None Example 24 Example 24 Composition 70 45 days Placebo 70 None Example 25 Example 25 Composition 70 45 days Placebo 70 None Example 26 Example 26 Composition 70 45 days Placebo 70 None Example 27 Example 27 Composition 70 45 days Placebo 70 None Example 28 Example 28 Composition 70 45 days Placebo 70 None Example 29 Example 29 Composition 70 45 days Placebo 70 None Example 30 Example 30 Composition 70 45 days Placebo 70 None Example 31 Example 31 Composition 70 45 days Placebo 70 None Example 32 Example 32 Composition 70 45 days Placebo 70 None Example 33 Example 33 Composition 70 45 days Placebo 70 None Example 34 Example 34 Composition 70 45 days Placebo 70 None Example 35 Example 35 Composition 70 45 days Placebo 70 None Example 36 Example 36 Composition 70 45 days Placebo 70 None Example 37 Example 37 Composition 70 45 days Placebo 70 None Example 38 Example 38 Composition 70 45 days Placebo 70 None Example 39 Example 39 Composition 70 45 days Placebo 70 None Example 40 Example 40 Composition 70 45 days Placebo 70 None Example 41 Example 41 Composition 70 45 days Placebo 70 None Example 42 Example 42 Composition 70 45 days Placebo 70 None Example 43 Example 43 Composition 70 45 days Placebo 70 None Example 44 Example 44 Composition 70 45 days Placebo 70 None Example 45 Example 45 Composition 70 45 days Placebo 70 None Example 46 Example 46 Composition 70 45 days Placebo 70 None Example 47 Example 47 Composition 70 45 days Placebo 70 None Example 48 Example 48 Composition 70 45 days Placebo 70 None Example 49 Example 49 Composition 70 45 days Placebo 70 None Example 50 Example 50 Composition 70 45 days Placebo 70 None Example 51 Example 51 Composition 70 45 days Placebo 70 None Example 52 Example 52 Composition  9 30 days Placebo 70 None Example 53 Example 53 Composition  3 30 days Placebo 70 None Example 54 Example 54 Composition 70 45 days Placebo 70 None Example 55 Example 55 Composition 70 45 days Placebo 70 None Example 56 Example 56 Composition 70 45 days Placebo 70 None Example 57 Example 57 Composition 70 45 days Placebo 70 None Example 58 Example 58 Composition 70 45 days Placebo 70 None Example 59 Example 59 Composition 70 45 days Placebo 70 None Example 60 Example 60 Composition 70 45 days Placebo 70 None Example 61 Example 61 Composition 70 45 days Placebo 70 None Example 62 Example 62 Composition 70 45 days Placebo 70 None Example 63 Example 63 Composition 70 45 days Placebo 70 None Example 64 Example 64 Composition 70 45 days Placebo 70 None Example 65 Example 65 Composition 70 45 days Placebo 70 None Example 66 Example 66 Composition 70 45 days Placebo 70 None Example 67 Example 67 Composition 70 45 days Placebo 70 None Example 68 Example 68 Composition 70 45 days Placebo 70 None Example 69 Example 69 Composition 70 45 days Placebo 70 None Example 70 Example 70

GENERAL CONCLUSION

The comparative tests clearly prove that the 70 compositions of Table C of the present invention provide unexpected and surprising results in vivo. The synergistic combination of components of examples 1 to 70 provide an unexpected and surprising therapeutical effect. 

What is claimed is:
 1. A method of treating a viral disease in a patient, comprising: administering to a patient in need thereof a synergistic combination of (−)-Carvone, (+)-Carvone, Trans-Geraniol, and at least one more component selected from the group consisting of Eugenol methylether, Linalooloxide, (cis+trans)-1,2-(+) Limonene oxide, (+/−)-Isomenthol, Eugenol, Trans-Nerolidol, (cis+trans)-Nerolidol, and Lavendulol; wherein the synergistic combination comprises between 10 and 35 wt % (−)-Carvone, between 10 and 35 wt % (+)-Carvone, between 10 and 35 wt % Trans-Geraniol, and at least 0.5 wt % of the at least one more component and is synergistic with respect to an antiviral effect of the (−)-Carvone, (+)-Carvone, trans-geraniol, and the at least one more component; and wherein the (−)-Carvone and (+)-Carvone, the trans-Geraniol, and the at least one more component are present in the composition in an amount effective for treatment of a viral disease caused by at least one of a Herpes Virus, a Rotavirus, a Porcine Reproductive and Respiratory Syndrome virus, and a Papilloma virus wherein the viral disease in the patient is selected from a group consisting of a Herpes Virus, a Rotavirus, a Porcine Reproductive and Respiratory Syndrome virus, and a Papilloma virus.
 2. The method of claim 1 wherein the antiviral composition is formulated for oral, nasal, pulmonary, or parenteral administration.
 3. The method of claim 1 wherein the antiviral composition is formulated as a disinfectant.
 4. The method of claim 1 wherein the antiviral composition is formulated for ex vivo use as viral inhibitor.
 5. A method of treating a patient infected with a virus, comprising: administering to a patient in need thereof a synergistic combination of (−)-Carvone, (+)-Carvone, Trans-Geraniol, and at least one more component selected from the group consisting of Eugenol methylether, Linalooloxide, (cis+trans)-1,2-(+) Limonene oxide, (+/−)-Isomenthol, Eugenol, Trans-Nerolidol, (cis+trans)-Nerolidol, and Lavendulol; wherein the synergistic combination comprises between 10 and 35 wt % (−)-Carvone, between 10 and 35 wt % (+)-Carvone, between 10 and 35 wt % Trans-Geraniol, and at least 0.5 wt % of the at least one more component and is synergistic with respect to an antiviral effect of the (−)-Carvone, (+)-Carvone, trans-geraniol, and the at least one more component; and wherein the (−)-Carvone and (+)-Carvone, the trans-Geraniol, and the at least one more component are present in the composition in an amount effective for treatment of a viral disease caused by at least one of a Herpes Virus, a Rotavirus, a Porcine Reproductive and Respiratory Syndrome virus, and a Papilloma virus wherein the virus in the patient is selected from a group consisting of a Herpes Virus, a Rotavirus, a Porcine Reproductive and Respiratory Syndrome virus, and a Papilloma virus. 